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Abstract

In S. aureus, the iron-scavenging siderophores staphyloferrin A and staphyloferrin
B are synthesized by enzymes encoded within the sfa and sbn gene clusters, respectively.
This work details the in vitro functional characterization of the Sbn enzymes responsible
for synthesizing staphyloferrin B. As demonstrated through UV-vis spectrophotometric
enzymatic assays and LC-ESI-MS experiments, staphyloferrin B can be synthesized in
vitro by incubating purified Sbn enzymes (SbnCEFH) with fundamental components of
the siderophore such as L-2,3-diaminopropionic acid, citric acid, and alpha-ketoglutaric
acid. Furthermore, a novel iron-regulated citrate synthase has been characterized and is
named SbnG, which condenses acetyl-CoA with oxaloacetate to form the citric acid
component of staphyloferrin B. Finally, in vitro prepared staphyloferrin B was
biologically active in that it was capable of binding and supplying iron, through the
SirABC transporter, to S. aureus. With functional characterization of the Sbn enzymes
and their corresponding reaction products, a biosynthetic pathway for staphyloferrin B is
proposed.

Keywords: Staphylococcus aureus, siderophore, iron, NIS synthetases, citric acid, aketoglutarate, L-2,3-diaminopropionic acid, citrate synthase, biosynthesis, ABC
transporter, LC-ESI-MS, ATP, PLP, hydroxylamine, DTNB
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Chapter 1:
Introduction

2

1.1. The Staphylococci
1.1.1. Description of the Genus
The name Staphylococcus originates from a combination of two Greek words that
describe the microscopic appearance of these bacteria. The first half of the name staphylé
suggest that the organism resembles a “bunch of grapes” while the second half of the
name kókkos stands for “grain or berry”. Therefore, species under the genus
Staphylococcus would appear as clusters of round (cocoid) cells much like a bunch of
grapes when viewed under a microscope. Members of the Staphylococcus species are
Gram-positive, non-spore forming, facultative anaerobes and are commonly distinguished
from other Gram-positive coccoid bacteria by the presence the enzyme catalase. The
organisms are also remarkably salt tolerant up to 15% NaCl, pH tolerant from pH 4.8 to
9.4 and resistant to dessication (1,2). The genome sizes among the staphylococci are
approximately 2-3 Mbp with a mol % G + C between 30-39 (1). Staphylococcal genomes
can contain prophages but extra-chromosomal DNA elements such as plasmids are very
rare. Through DNA-DNA hybridization and 16S rRNA sequence analysis, there are now
41 species and 24 subspecies within the genus Staphylococcus (1). The genus is further
divided into two groups based on possession of coagulase which is an enzyme that
converts fibrinogen to fibrin leading to blood clotting. The coagulase-positive
Staphylococcus species include S. aureus, S. delphini, S. hyicus, S. intermedius, S. lutrae,
S. pseudintermedius and S. schleiferi subsp. coagulans which are pathogens commonly
isolated from humans and mammals (3-7). In blood, the activity of coagulase allows
these staphylococci to shield themselves with a coat of fibrin and this in effect serves as a
barrier against host phagocytic defenses. Meanwhile, several clinically relevant
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coagulase-negative

staphylococci

include

S.

epidermidis,

S.

saprophyticus, S.

haemolyticus, and S. lugdunensis (1). However, the most virulent member of the
Staphylococcus genus is the coagulase-positive S. aureus.

1.1.2

Human colonization and pathogenesis of S. aureus
S.

aureus is normally part of the human flora as a commensal bacterium. The main

habitat on the human body for S. aureus is the anterior nares although the bacterium can
also be found on the skin, throat, underarms, gut, groin and vaginal areas (2). In terms of
the human population, approximately 20% of the population is persistently colonized by
S. aureus, 60% are intermittently colonized, and the remaining 20% are non-carriers of S.
aureus (1,2). Therefore, the majority of the population has, at least at one point in time,
been colonized by S. aureus. Members of the population that are at the greatest risk for
infection are the elderly and immunocompromised patients. However, certain strains of S.
aureus are equally capable of causing disease in otherwise young and healthy people. The
most common infection caused by S. aureus are low-grade skin infections; however, upon
breaching of the epithelial barrier, S. aureus can inflict more serious diseases such as
endocarditis, pneumonia, bacteraemia, muscle/tissue abcesses, septic arthritis, and
osteomylelitis (1,2). Furthermore, S. aureus does not necessarily need to be present in the
host order to cause disease since the pathogen can produce a battery of toxins that can
lead to toxin-mediated maladies such as food poisoning, toxic shock syndrome,
enterocolitis, and infant scalded skin syndrome (1,2).
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1.1.3. S. aureus and drug resistance
Efforts to treat and manage S. aureus infections have been constantly hampered
by the bacterium’s ability to rapidly develop antibiotic resistance. Since the introduction
of penicillin and its brief successful treatment of S. aureus infections in the 1940s-1950s
(8), clinical isolates of the pathogen have acquired resistance to every drug regimen
including next-generation penicillin derivatives (or beta-lactam antibiotics) such as
cephalosporins, carbapenems, cephamycins, and monobactams. Beta-lactam antibtiotics
bind and inhibit the action of penicillin-binding proteins (PBPs), which are enzymes
involved in crosslinking peptidoglycan during cell wall synthesis (1). However, the
majority of S. aureus strains possesses the enzyme beta-lactamase which hydrolyzes the
beta-lactam ring and this allows PBPs to continue with cell wall synthesis. To circumvent
this, semi-synthetic beta-lactam antibiotics (e.g. methicillin) were developed with the
property of low affinity for beta-lactamase. However, the widespread use and
overdependence on methicillin gave rise to methicillin-resistant S. aureus (MRSA) which
possesses a new PBP called PBP2a (8). PBP2a has low affinity for all beta-lactams and
thus allows for continued cell wall synthesis even in the presence of high concentrations
of beta-lactams. To further complicate the problem, drug-resistant S. aureus have spread
from hospital to community settings with the emergence of community-acquired MRSA
as well as continued evolution of drug resistance. Strains of MRSA are also commonly
resistant to

other classes

of antibiotics

such as rifampin,

fluoroquinolones,

aminoglycosides, tetracyclines, and chloramphenicol (8). By the late 1990s, health care
professionals have resorted to vancomycin and teicoplanin as the last effective drugs
against S. aureus (8). These drugs are glycopeptide antibiotics and they also target cell
wall synthesis but function slightly differently by masking peptidoglycan substrates rather
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than directly inhibiting the biosynthetic enzymes.

Unfortunately by 2002, S. aureus

added vancomycin to its antibiotic resistance repertoire and the first cases of vancomycinresistant S. aureus (VRSA) were reported by the Centers for Disease Control and
Prevention (8). The persistence of S. aureus in pathogenesis and antibiotic resistance
allow it to stand as a formidable foe against healthcare workers and researchers of today
and tomorrow.

1.1.3

Virulence Factors of S. aureus
The success of S. aureus as a pathogen can be owed to its plethora of virulence

factors. A few important examples will be highlighted in this section to provide a
perspective on how S. aureus colonizes the host, evades or modulates the immune
response and, ultimately, establishes infection. Please refer to Table 1 (adapted and
modified from Crossley et al. 2009) for a detailed summary of virulence factors in S.
aureus. S. aureus expresses several adhesin proteins on its surface which undergo
extensive protein-protein contacts with host serum proteins or extracellular matrix
proteins. Therefore, these cell surface proteins are classified as microbial surface
components recognizing adhesive matrix molecules (MSCRAMMs) (1). These proteins
are covalently anchored at the C-terminus to the peptidoglycan by an enzyme called
sortase A, which recognizes a cell wall sorting motif “LPXTG” on the protein (9). One
example of such a surface protein is Protein A which functions by binding onto the Fc
portion of IgG antibodies and this would reorient the antibody in a direction away from
the bacterium. As a result, the cell is protected from antibody-mediated immune
responses such as antibody-mediated opsonization (10). Other MSCRAMMs include
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Table 1.1. List of Staphylococcus aureus virulence factors
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Gene

Virulence factors

Function/Effect

C ell W all com ponents

Role in nasal colonization
Causes septic shock
Causes septic shock

Teichoic acid
Lipoteichoic acid
Peptidoglycan
Surface adhesions

Protein A

spa

Clumping factors A and B

clfA, claB

Fibronectin-binding proteins A and B
Collagen adhesion

fnbA B
cna

Binds Fc portion of IgG molecules to
inhibit phagocytosis
Allows for adhesion to host tissues
Provides phagocytic resistance
Allows for adhesion to host tissues
Allows for adhesion to collagen

Secreted adhesions

Extracellular fibrinogen-binding
protein
Extracellular matrix-binding protein

efb

Extracellular adhesion protein (EAP)

eap

emp

Formation of staphylococcal communities
leading to abscess formation
Formation of a pseudocapsule for
enhanced resistance to host defenses

E xopolysacchardes

Capsule

cap

Polysaccharide intercellular adhesion

icaADBC

Polysaccharide capsule production
Inhibits opsonophagocytosis
Leads to biofilm formation
Provides resistance to phagocytosis and
antimicrobial peptides

E xotoxins

Hla, hlb, hid,
hlg
lukFS-PV
etA, etB, etC,
etD
tstH
seAE,seG, sei, seti,
seJ, seV

Causes host cell lysis including
erythrocytes and white blood cells
Damages leukocyte membrane
Causative agent of staphylococcal scalded
skin syndrome
Superantigen and toxic shock syndrome
Leads to gastrointestinal illness and may
display superantigenicity

sspA
sspB

Cleaves extracellular proteins
Cleaves extracellular proteins

Iron-regulated surface determinants

Isd genes

Staphyloferrin A
Staphyloferrin B

sfaA-D
sbnA-I

Cell surface heme binding proteins
involved in heme uptake
Iron-chelating siderophore
Iron-chelating siderophore

a-toxin, P-toxin, 5-toxin, y-toxin
Panton-Valentine leukotoxin
Exfoliative toxins
Toxic shock syndrome (TSST)-l
Staphyloccal enterotoxins

E nzym es

Serine protease
Cysteine protease
Iron A cquisition

R egulators

Accessory gene regulator

agr

Staphylococcal accessory regulator

sar genes

Exoprotein expression

saeRS

Involved in quorum sensing
Regulates expression of cell-surface and
secreted proteins
Regulates the agr system
Regulation of extracellular and surfaceassociated virulence factors
Regulation of exotoxins
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fibronectin-binding proteins FnbA and FnbB as well as fibrinogen-binding proteins ClfA
and ClfB (1,11). In addition to proteins, cell surface polysaccharides of S. aureus also
carry roles in virulence. For instance, teichoic acid aids in adherence onto nasal surfaces
and endothelial cells (12,13). Other cell surface polysaccharides that serve a role in
virulence include peptidoglycan as well as lipoteichoic acid which modulate the
recruitment of neutrophils as well as activation of septic shock (14,15). Additional
polysaccharides that confer protection to S. aureus from host immune responses include
capsular polysaccharide (prevents phagocytosis) as well as polysaccharide intercellular
adhesins that are involved in biofilm formation (also prevents phagocytosis as well as
resistance to antibiotics) (1). Once infection has been established, S. aureus will produce
numerous toxins and proteases that will lyse host cells or degrade cellular components
such as extracellular proteins. Several examples of S. aureus toxins include exfoliative
toxins A and B (ETA and ETB) which lead to the skin sloughing disease called
staphylococcal scalded skin syndrome (16). S. aureus is also known for causing toxic
shock syndrome due to the production of toxic shock syndrome toxin-1 (TSST-1). This
toxin is a superantigen which nonspecifically activates T cells leading to fevers, rashes,
multi-organ failure, and eventually death (1,17). The pathogen also produces another
superantigen-like toxin in contaminated foods. This toxin is actually an enterotoxin that
leads to food poisoning which is typified by serious vomiting and diarrhea (17,18). Note
that S. aureus does not necessarily need to be present in the host in order for food
poisoning symptoms to develop. The expansive list includes five known cytolytic toxins
which are a-, (3-, y-, and ô- toxins as well as the Panton-Valentine leukotoxin. These are
pore-forming toxins that lead to osmotic imbalance and eventual lysis of host cells. The
a- and P-toxins are known to target and lyse erythrocytes while the y-toxin causes lysis in
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a variety of different cell types (1,19). The last two exotoxins 8- toxin and PantonValentine leukotoxin are capable of targeting and causing lysis of white blood cells (20).
Lastly, S. aureus secretes extracellular serine and cysteine proteases, which are involved
in degradation of host extracellular proteins (1). Other secreted exoenzymes include
nucleases, lipases, and hyaluronidases that further degrade host intracellular and
extracellular components (1). Many of the S. aureus virulence factors are regulated by the
agr and sar systems. The agr system is a quorum sensing tool used to regulate the
expression of the mentioned exoproteins and cell surface proteins with respect to cell
density (21). This system allows for S. aureus to express virulence factors that are
necessary for colonization and adhesion during early stages of infection before switching
to expression of invasive and degradation factors such as proteases and toxins during late
stages of infection. Meanwhile, the sar system provides an additional layer of regulatory
control over these virulence factors and also regulates the agr system itself (1,22,23).
In recent years, research on S. aureus pathogenesis and physiology has revealed
that nutrient acquisition such as iron uptake is critical for successful S. aureus
pathogenesis and establishment of infection. Therefore, the systems involved in the
acquisition of this metal from the host represent a different class of virulence factors
altogether and such systems will be the focus of this thesis from here on.
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1.2 Iron
1.2.1

The Chemical and Physical Nature of Iron
Iron is an extremely abundant element on Earth and is located on the periodic

table as a Group 8 element with atomic number 26. Iron can exist in a wide range of
reversible oxidation states from -2 to +6 but the +2 (ferrous) and +3 (ferric) forms of iron
are the most common. Due to iron’s flexible oxidation status, it becomes an extremely
useful element for electron transfer reactions (24). Under aerobic environments and at a
neutral pH, the predominant form of iron is ferric iron and has a tendency to form
polymers of iron hydroxide precipitates due to the element’s propensity for being
oxidized as well as its lack of solubility (24). As a result, the solubility constant of ferric
iron is 1.4 x 10‘9 M under these conditions (25,26). By comparison, ferrous iron has a
solubility constant of 10'1 M under identical conditions (24). However, iron in the more
soluble ferrous state presents its own problems especially within an intracellular
environment. Reducing conditions inside a cell will reduce ferric iron to the ferrous state
and this form of iron can react with hydrogen peroxide, superoxide, or nitric oxide to
form hydroxide radicals and reactive oxygen species through a mechanism called the
Fenton reaction (26). Hydroxide radicals and reactive oxygen species are extreme
oxidizing agents with the threat of damaging cellular membranes and DNA (27). The next
section will discuss the biological roles of iron as well as the safe regulation and handling
of this precious metal by both host and pathogenic bacteria.
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1.2.2

The Biological Nature of Iron
Iron is an essential nutrient for all known organisms except for one species of

Lactobacilli and Borrelia burgdorferi which can utilize manganese and cobalt in place of
iron (24,28). Upon successful colonization of a host, a pathogen would be immersed in an
environment containing all of the major nutrient sources and elements that can sustain life
and permit proliferation of the organism. Nutrients such as organic carbon, nitrogen,
amino acids, nucleotides, phosphates, sulphates, as well as biologically relevant divalent
metals like magnesium, manganese, and zinc, are readily found in host tissue and fluids
(26). However one nutrient, although abundantly present in the host, is a constant obstacle
for pathogens to acquire and that is iron.
The redox potential of iron makes it a suitable cofactor for critical housekeeping
enzymes that synthesize amino acids and nucleotides. Furthermore, the electron
transferring capabilities of iron allow it to be a participant in electron transport during
cellular respiration as well as photosynthesis (29). Iron is also an essential cofactor for
enzymes involved in redox reactions through its incorporation into iron-sulfur clusters or
as part of the reactive centers of heme-containing proteins (29). In fact, more than 100
different enzymes involved in primary and secondary metabolism require iron as a
cofactor (30). Therefore, in order for a pathogen to continue to perform and maintain all
of these essential cellular processes during infection, it needs to acquire iron from the
host. However, the concentration of free iron in the host is much too low to support the
micromolar concentrations required for bacterial proliferation.

This low iron

concentration in the host is achieved by innate immune proteins that sequester free iron
from pathogenic bacteria (29,31). Examples of extracelluar iron-sequestering proteins
include transferrin (in blood/serum) and lactoferrin (in milk and mucosal secretions)
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whereas intracellular iron-storage proteins include ferritin and hemoproteins such as
hemoglobin (in erythrocytes) (24,26,29,31,32). Specifically, transferrin and lactoferrin
have an extremely high affinity for Fe3+ (ferric) iron with an association constant (Ka) of
1020 M '1versus a much lower specificity for Fe2+ (ferrous) iron with a Kd of 103 M'1. Both
proteins serve as iron chelators but transferrin has the additional function of being an iron
carrier/transporter in the body (29). Intracellularly, host cells also store iron within a large
globular shell-like protein called ferritin, which can house thousands of ferric iron atoms
(33). These proteins serve to store iron as well as sequester iron in the cytoplasm to
prevent unwanted cytotoxic effects (29).
Heme-iron is another source of iron for pathogenic bacteria and unlike free iron,
pathogens only require nanomolar (a thousand-fold less than free iron) concentrations to
survive (29). Sources of heme-iron include hemoglobin (oxygen transport protein found
in erythrocytes), haptoglobin-hemoglobin complexes (haptoglobin forms this complex
with hemoglobin upon erythrocyte lysis in serum), hemopexin (captures free heme
released into serum), and serum albumin (most abundant serum protein) (29). However,
despite all these methods of iron sequestration and storage strategies developed by
mammalian hosts to limit free iron concentration in serum to 10"24 M (34), pathogenic
bacteria have still evolved sophisticated iron acquisition strategies to acquire this nutrient
against all odds during infection.

1.2.3

Iron-regulation in Bacteria
As mentioned earlier, organisms must carefully regulate their intracellular iron

status as too little or too much iron will have negative consequences. Pathogens,
including S. aureus, encode various iron transporters (uptake or efflux) to maintain iron
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homeostasis such that a balanced and non-toxic concentration of intracellular iron is
achieved. Genes that are associated with iron homeostasis are usually regulated by central
regulatory proteins and these proteins will direct the cell to express the necessary
transport systems with respect to fluctuating iron levels in the environment. The ferric
uptake regulator (Fur) protein is one such protein that controls the expression of iron
acquisition systems in bacteria and was originally described in Escherichia coli as a
transcriptional repressor of iron-regulated genes (26,29,35,36). Similarly, the Fur protein
regulates a series of iron transport systems in S. aureus (to be further discussed later). The
18-kDa Fur protein is functionally active as a homodimer and this homodimer has an
affinity for binding ferrous (Fe2+) iron atoms (each monomer binds one atom of iron)
thereby making iron a co-repressor. Once Fur is iron-loaded, it will gain affinity for
binding genomic DNA at a particular sequence called the Fur box which is a 19 base-pair
inverted repeat (5-GATAATGATAATCATTATC-3') (35). Specifically, the Fur box is
commonly located within the promoter region of iron-regulated gene clusters. Therefore,
when iron is abundant in the environment and the physiological requirement for iron has
been satisfied, ferrous (Fe2+) iron will bind onto the Fur protein and the iron-protein dimer
complex will bind onto the Fur box at the promoter regions to block transcription of
downstream iron-regulated genes. However, if the bacterium is iron-deficient, then the
lack of ferrous (Fe2+) iron atoms will not permit the Fur protein complex to bind the Fur
box to inhibit transcription of iron-regulated genes. Therefore, RNA polymerase will then
be allowed to proceed with transcription of downstream iron-acquisition systems (29). It
has also been noted that Fur regulates genes beyond iron (or heme) acquisition and, in
fact, potentially 50 to 100 different genes are under the influence of Fur regulation with
the function of such genes spanning from virulence factors to acid resistance (29,36,37).

14

For S. aureus, the Fur protein allows for simultaneous regulation of iron
homeostasis and virulence factor expression. A recent study has shown that fur mutants of
S. aureus show increased susceptibility to neutrophil killing and exhibit a weaker
virulence phenotype in a murine pneumonia model of infection (38). Therefore, Fur is not
only involved in iron homeostasis but is also an active contributor towards overall
virulence of S. aureus. In the next section, we will discuss the two avenues of bacterial
iron acquisition that are regulated by the Fur protein. The first strategy involves
scavenging of free iron in the environment using secreted high-affinity iron-chelators and
the second strategy employs the use of heme-transport systems.

1.3

Bacterial Iron-uptake

1.3.1

Bacterial Heme-iron acquisition
This section will present several heme-iron acquisition strategies that are

employed by both Gram-negative and Gram-positive bacteria. Heme-iron represents the
most abundant source of iron and it alone accounts for approximately 80% of the total
iron pool in mammals (39-41) and the sources of heme have been mentioned above as
well. Heme is 616 Da and is a lipophilic, planar molecule. Structurally, it consists of a
tetrapyrrole ring (or a macrocyclic porphyrin) with an iron atom encased in the center.
The oxidation state of the iron atom may be ferric (Fe3+) or ferrous (Fe2+). Therefore,
ferric-heme is formally called “hemin” as opposed to ferrous-heme which is simply
“heme”. The advantage of having iron encased in the tetrapyrrole ring is that the catalytic
potential of iron actually increases by 5-10 orders of magnitude and this allows heme to
be a critical cofactor for many proteins or enzymes involved in oxygen storage/transport
as well as peroxide and oxygen radical elimination (42). Much like free iron, heme
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concentrations must also be carefully regulated as increased levels can present toxic
complications to the cell. Due to the hydrophobic nature of heme and its low molecular
weight, the molecule tends to easily insert within membranes which can lead to distortion
of cellular or organelle membranes (43).
Gram-negative bacteria employ a diverse set of strategies to acquire heme-iron.
The first strategy utilizes hemolysins to lyse erythrocytes such that hemoglobin will be
released and this can be followed by release of heme from the protein. Afterwards, outer
membrane heme receptors on the bacteria will be available to capture the liberated heme
or to remove heme from hemoproteins in serum (see Figure 1.1). At this point, the
mechanism of heme passage from the outer membrane receptor to the periplasmic space
is an energy-dependent process that employs the TonB-ExbB-ExbD inner membrane
complex. Normally, the heme ligand cannot freely pass through the outer membrane
receptor because the base of this receptor is actually blocked or “corked” by protein
protein interactions involving its own N-terminal domain with the C-terminal periplasmic
extensions of the inner membrane TonB protein. Therefore, large-scale conformational
changes must occur to “uncork” the base of the outer membrane protein to permit passage
of the heme into the periplasm (44-46). The inner membrane ExbB-ExbD complex
harnesses the energy from a proton motive force and transduces this energy towards
TonB such that a conformational change will be induced. Such conformational changes
will “uncork” the base of the outer membrane receptor by altering the protein-protein
interactions between the receptor’s N-terminal domain (TonB Box) and periplasmic
extensions of TonB. With the “cork” removed, heme can then freely pass into the
periplasm where a periplasmic heme-binding protein will capture the heme (43,47). The
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Figure 1.1. Heme or siderophore transport in Gram-negative bacteria. The ironsiderophore or iron-heme complex is first bound by a high-affinity outer membrane
receptor. Energy transduction by the inner membrane TonB-ExbB-ExbD complex
coupled to conformational changes of the C-terminal periplasmic domain of TonB with
the N-terminal “TonB Box” of the outer membrane receptor allows for “uncorking” of the
base of the receptor. This permits entry of the iron-loaded ligand into the periplasm where
it is now bound by a periplasmic binding protein for subsequent delivery to a cognate
ABC transport system. The coupled energy from ATP hydrolysis (by the associated
ATPase subunits) permits shuttling of the iron substrate into the cytoplasm.
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heme-loaded periplasmic binding protein will then dock onto a dedicated inner membrane
ATP-binding cassette (ABC) transporter. This type of transport system comprises a
ligand-binding protein (the periplasmic heme-binding protein), a transmembrane
permease, and an ATPase. The hydrolysis of ATP by the ATPase provides the coupled
energy for inducing conformational changes to the transporter in order to deliver the
heme ligand through the transmembrane permease and into the cytoplasm (48). Examples
of this heme transport system have been studied in various bacteria including Yersinia
enterocolitica (the hemR-hemSTUV system) (49), Yersinia pestis (the hmuRSTUV system)
(50), Shigella dysenteriae (the shuASTUV system) (51,52), and Pseudomonas aeruginosa
(thephuRSTUVW system) (53,54).
The second heme transport strategy in Gram-negative bacteria utilizes secreted
proteins called hemophores. Hemophores are secreted into the extracellular environment
and will scavenge free heme or extract heme from hemoproteins and then return to the
cell via recognition of a specific hemophore outer membrane receptor (43). The
internalization of heme from the outer membrane receptor follows the TonB-dependent
mechanism as described earlier. The best-studied hemophore system is the hasADEB
system of Serratia marcescens (43,55) in which HasA is the hemophore protein that
scavenges extracellular heme before passing it to the outer membrane receptor HasR (56).
Similar hemophore systems can also be found in P. aeruginosa, P. fluorescens, Y. pestis,
and Y. enterocolitica (43,55).
The third strategy of heme-iron acquisition in Gram-negative bacteria (and
possibly in Gram-positive bacteria as well) involves the use of an enzyme that belongs to
the family of dye-decolorizing peroxidases (Dyp-type peroxidases) which has recently
been described to extract iron out of the tetrapyrrole ring of heme resulting in the release
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of free iron and intact protoporphyrin IX (heme minus the central iron atom) (57). Two
such enzymes were described in E. coli and they were called YfeX and EfeB in which
YfeX resides in the cytoplasm and EfeB is found in the periplasm after translocation out
of the cytosol by the twin-arginine translocation (TAT) system (57). Specifically, EfeB is
iron-regulated and is proposed to be involved in ferrous (Fe2+) iron uptake under acidic
conditions (58). Homologues of EfeB and YfeX are extremely conserved across Gram
positive and Gram-negative species. For example, the S. aureus strain Newman is
predicted to possess such a peroxidase/transport system with locus tags NWMN_0336,
NWMN_0337, and NWMNJ3338 which are predicted to encode a lipoprotein receptor,
dyp-type peroxidase, and iron permease, respectively.
Heme-iron acquisition systems in Gram-positive bacteria are differ greatly from
those of the Gram-negative counterpart. The best characterized heme transport systems in
Gram-positive bacteria involve cell wall-anchored proteins that capture either free heme
or heme from hemoproteins (i.e. hemoglobin). This strategy is called the iron-regulated
surface determinant (Isd) system and it has been well studied in S. aureus (see Figure
1.2) and Bacillus anthracis, although a homologous system has been identified in Listeria
monocytogenes as well (59-62). The number of Isd proteins on the cell surface involved
with heme transport can vary between organisms, but the concept is identical. Each cell
wall-anchored Isd protein will relay the heme molecule to the next and eventually the
heme will be passed to a high affinity ABC-type transport system for shuttling of the
substrate into the cytoplasm. The Isd system was initially identified by Taylor and
Heinrichs (2002) and Mazmanian et al. (2003) in S. aureus in which they observed that
transport of heme-iron from hemoglobin into the cytoplasm required the function certain
proteins. Later on, the system was assigned a proper nomenclature and it became clear
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that the locus consisted of nine genes which were all iron-regulated by the Fur protein
(1,63). The Isd system in S. aureus is arranged as five different transcriptional units
consisting of genes isdA, isdB, isdCDEFsrtBisdG, isdH, and isdl (39,63,64). The cell wall
anchored Isd proteins of S. aureus which are IsdA, IsdB, IsdC, and IsdH each have at
least one Near Iron Transporter (NEAT) domain that has been implicated in heme binding
(39). The proteins IsdA, IsdB, and IsdH are each covalently anchored to the cell wall by
Sortase A via recognition of a C-terminal LPXTG motif on these Isd proteins. However,
IsdC is uniquely anchored by Sortase B through recognition of a different C-terminal
motif which is NPQTN (61,63). Action of the S. aureus Isd system begins with
erythrocyte lysis (caused by a-toxin) leading to release of hemoglobin into the serum and
immediate formation of hemoglobin-haptoglobin complexes. These protein complexes
are captured by the first Isd protein which is IsdH (65). IsdB is the next protein in the
pathway and it is responsible for binding onto hemoglobin (63,66) and will presumably
extract the heme from the hemoprotein. From here, either IsdB or IsdH can pass the
extracted heme to IsdA and then IsdA will pass the heme towards IsdC, the central
conduit of this heme transfer pathway. Finally, IsdC will pass the heme to the ABC
transport system which is IsdDEF for active transport into the cytoplasm (39,67,68). Once
heme has reached the cytoplasm, the heme monoxygenases IsdG and Isdl will degrade
heme into a by-product called staphylobilin (69,70) in order to release the iron atom for
its next physiological purpose.
As mentioned previously, heme-iron acquisition systems promote S. aureus
pathogenesis. S. aureus mutants in genes isdA, isdB, isdC, isdG, and isdl display an
attenuated virulence phenotype with decreased bacterial load in heart, kidney, spleen, and
liver organs of mice (66,70). Such phenotypes correlated with decreased growth in iron-
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restricted media with heme being provided as the sole iron source (70,71). Beyond hemeiron acquisition, the protein IsdA also appears to have a role in colonization for S. aureus,
as the protein has been characterized to interact with various extracellular matrix and
serum proteins (72,73), as well as carrying a role in protection against host innate immune
defenses by increasing the hydrophobicity of the cell surface (74,75).
However, not all Gram-positive pathogens employ the Isd system for heme
transport. The pathogen Streptococcus pyogenes also possesses a heme acquisition system
but it is much simpler than the Isd system described in S. aureus. It is called the Shr/Shp
system in which both Shr and Shp are surface heme-binding proteins like the Isd proteins.
This system also contains an ABC-type transporter for its substrate heme called the
HtsABC transporter (76). The Shr protein will initially bind heme before passing it to Shp
and the heme would then be relayed to the heme-binding lipoprotein receptor HtsA for
active transport of the heme molecule into the cytoplasm.
Heme-iron acquisition is clearly a potent strategy for iron uptake in pathogenic
bacteria utilizing both intricate and elegant pathways often involving multiple proteins.
However, relying on heme-iron acquisition alone may not be sufficient for pathogenesis,
and therefore a second strategy for iron uptake would be necessary under circumstances
even when heme-iron is not abundant.
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Figure 1.2. The Isd heme transport system of S. aureus. Heme is transported across the
cell wall via several cell wall-anchored Isd proteins and a dedicated ABC transport
system shuttles the heme across the cell membrane. Heme is initially bound to IsdB or
IsdH which then transfers the heme to IsdA. IsdA then transfers the heme to IsdC which
is buried within the cell wall. The receptor lipoprotein IsdE then receives the heme from
IsdC before ATP hydrolysis occurs that will permit shuttling of the heme through the IsdF
transmembrane permease. Once heme is inside the cell, the monoxygenases Isdl or IsdG
will degrade the heme to release iron. Note that each red square on the protein in the
figure denotes the NEAT domain responsible for binding heme for that particular Isd
protein. Proteins such as IsdB and IsdH have more than one NEAT domain but only one
exhibits heme-binding ability.

23

F ree h em e

(or extracted from hemoglobin)

IsdH

Extracellular
Space

Cell Wall

Cell Membrane

Cytoplasm

24

1.3.2 Biological and Physico-chemical Properties of Siderophores
The name siderophore means “iron carrier” in Greek and is the second avenue of
bacterial iron uptake as well as the remaining focus of this thesis. Siderophores are
secreted high-affinity low molecular weight (< 1 kDa) chelators that scavenge iron in the
environment and return to the cell through recognition by ferric-siderophore ABC
transport systems (30). Siderophore biosynthesis is initiated once intracellular
concentrations of iron have dropped below the minimum threshold to support microbial
life (10'6 M). At this point, the Fur protein will permit transcription of one or more
siderophore biosynthetic and/or uptake genes (30). Note that siderophore production is
not limited to prokaryotes, for eukaryotes such as fungi and even some higher plants can
also produce siderophores to acquire iron (30). Due to the iron-chelating properties of
siderophores, the molecules themselves are overall electronegative and will therefore
coordinate and solubilize ferric (Fe3+) iron from the environment.
The composition of siderophores is complex with building blocks consisting of
amino acids, non-proteinogenic amino acids, carboxylic acids, alcohols, amines, and
aromatics, as well as modified versions of these molecules. The elemental composition of
siderophores is largely carbon as the skeletal backbone with electrons from oxygen and
sometimes nitrogen as ligands for iron coordination. Synthesis of these siderophores will
be further discussed in a later section. Due to the diversity of siderophores, these
molecules have been categorized depending on the oxygen-containing functional groups
used to coordinate the iron atom. Siderophores currently belong to one of four different
major classes which are catecholates (or “aryl-capped” siderophores), phenolates,
hydroxamates, and a-hydroxy-carboxylates (Figure 1.3). However, the discovery of more
siderophores has complicated this classification scheme and some siderophores are now
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classified as mixed/hybrid-type siderophores where the siderophore uses at least two
different functional groups to coordinate the iron atom (30). For example, the siderophore
enterobactin from E. coli represents the model catecholate siderophore due to the use of
catechol functional groups in iron coordination (34). Meanwhile, the hydroxamate-type
siderophore alcaligin (from Bordetalla spp.) and the carboxylate-type siderophore
achromobactin (from Pseudomonas syringae) use hydroxamate and carboxylate
functional groups to coordinate iron, respectively. An example of a mixed-type
siderophore would be mycobactin T (from Mycobacterium tuberculosis) which employs
both phenol and hydroxamate functional groups to coordinate iron and thus making it a
phenolate-hydroxamate-type siderophore (30).
Siderophore chelation of an iron atom is driven by a gain in entropy of the
environment where ferric iron, which is normally solvated by six water molecules to form
an octahedral Fe(H20)6 complex (77), would lose this hydration shell once a siderophore
has arrived to displace the water molecules (thus creating disorder). Therefore, the watercoordinated iron atom is now replaced by siderophore-coordination. Most siderophores
bind to ferric iron in a 1:1 ratio but higher order stoichiometry may also be possible such
as in the case of pyochelin from Pseudomonas aeruginosa, which can use two pyochelin
molecules to bind one atom of iron (78). Once an iron-siderophore complex has formed, it
remains very stable because the oxygen atoms on the siderophore serve as strong Lewis
bases that have formed ionic-like bonds with ferric (Fe3+) iron, which is a strong Lewis
acid (30). In contrast, ferrous (Fe ) iron represents an extremely weak Lewis acid and so
maintaining strong ionic interactions with strong Lewis bases like oxygen are less
favourable. In fact, ferrous (Fe ) coordination would be more favourable if electron
donors were weaker Lewis bases such as nitrogen (30). Therefore, the affinity of
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siderophores for ferric (Fe3+) iron is magnitudes greater than ferrous (Fe2+) iron.
Furthermore, the association constant of siderophores with ferric iron has been estimated
to be 1030 M '1 suggesting extreme affinity (29).
Note that organisms do not necessarily always need to use the same siderophores
that they manufacture. Bacteria are also quite capable of utilizing siderophores made from
other bacteria (termed xenosiderophores) as long as a transport system is present to
recognize and uptake these ferric-xenosiderophore complexes (30). On a similar note,
pathogens have recently been described to be able to uptake host-derived
xenosiderophores or “pseudo-siderophores” in which host catecholamine stress hormones
have formed a hexacoordination complex with iron (3:1 or 2:1 ratio of hormone:iron) to
mimic a catecholate-type siderophore complex like enterobactin (79-81).
With a better understanding behind the chemical and physical nature of
siderophores, we will now examine the transport of ferric-siderophore complexes from
the extracellular environment to the bacterial cytoplasm.
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Figure 1.3. Representative siderophores from each major siderophore class. Shown
are representative siderophore structures from the catecholate, phenolate, hydroxamate,
and a-hydroxycarboxylate classes as well as hybrid-class siderophores. Characteristic
functional groups are highlighted for clarity. Siderophore structures were reproduced
according to Miethke and Marahiel (2007).
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1.3.3

Bacterial Siderophore-iron acquisition
Once a siderophore has bound a ferric iron atom, the ferric-siderophore complex

will return to the cell via recognition by a specific receptor and transport system. Since
the concentration of ferric-siderophores is much lower outside of the cell, and their
structures are either too bulky or charged for simple diffusion through the cell membrane,
active transport needs to be used to shuttle ferric-siderophores into the cytoplasm (29,34).
The mechanism of ferric-siderophore uptake for Gram-negative bacteria is highly similar
to the heme transport mechanism already described (see Figure 1.1). In comparison,
ferric-siderophore uptake in Gram-positive bacteria can be viewed as a more simplified
version of the Gram-negative mechanism (Figure 1.4). In this section, the E. coli
enterobactin transport system is provided as an example of Gram-negative ferricsiderophore transport and the next section will detail ferric-siderophore transport in
Gram-positive bacteria by examples from S. aureus.
For E. coli, transport of ferric-enterobactin initially occurs with binding of the
ferric-siderophore to its cognate outer membrane receptor FepA (34). The affinity of the
outer membrane receptors for ferric-siderophores is typically very high with nanomolar
dissociation constants (29) and FepA exhibits a binding constant of 50 nM for ferricenterobactin (82). In order for the ferric-siderophore to pass into the periplasm, the inner
membrane TonB complex needs to be used as in heme transport (described earlier)
(29,34) in order to transduce energy (from a proton motive force) to allow conformational
changes to occur so that the base of the FepA receptor is uncorked to allow passage of
ferric-enterobactin (29,83). Once the iron-siderophore complex has reached the
periplasm, it will bind onto a periplasmic binding protein (much like in heme transport)
that will then dock onto a corresponding ABC transporter. The periplasmic binding
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protein for ferric-enterobactin is FepB and has a dissociation constant of 30 nM (84).
Next, ferric-enterobactin is transported across the inner membrane and into the cytoplasm
through the dedicated ABC transporter comprised of FepD and FepG (transmembrane
permease units) as well as FepC (ATPase) (34). ATP hydrolysis followed by
conformational changes allows the shuttling of ferric-enterobactin into the cytoplasm.
Once inside the cell, dedicated hydrolases or esterases would cleave the siderophore or
reductases would reduce the ferric iron to ferrous iron to free the iron atom from the
chelator (29,30,34,85). The iron is then available for appropriate use inside the cell.
Ferric-siderophore transport in Gram-positive bacteria is much simpler than the
Gram-negative mechanism. The outer membrane receptor and TonB complexes are not a
factor in Gram-positive siderophore transport due to the obvious lack of an outer
membrane. However, an ABC transporter component is still present and in the place of a
periplasmic binding protein is a lipid-anchored binding protein responsible for binding
the ferric-siderophore complex and docking onto the ABC transporter (29).
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Figure 1.4. Siderophore transport in Gram-positive bacteria. Ferrated siderophore is
initially bound by a high-affinity receptor lipoprotein (anchored to the cell membrane).
This receptor protein is analogous to the function of the periplasmic binding protein
found in the periplasm of Gram-negative bacteria. The receptor then delivers the ferricsiderophore complex to the appropriate ABC transport system. The coupled energy from
ATP hydrolysis (by the associated ATPase subunits) permits shuttling of the iron
substrate into the cytoplasm.
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1.3.4

Siderophores of S. aureus

S. aureus is known to produce two siderophores called staphyloferrin A and
staphyloferrin B. Both siderophores belong to the a-hydroxycarboxylate siderophore
family and both have also been structurally and chemically characterized (Figure 1.5).
Through ion-paired high-performance liquid chromatography (HPLC) analysis of culture
supernatants from Staphylococcus hyicus grown under iron-restricted conditions,
chromatographic peaks corresponding to ferric-staphyloferrin A and ferric-staphyloferrin
B were identified (86). Notably, UV/Vis-spectrophotometry of these ferrated
siderophores showed a lack of charge-transfer bands between 420 nm and 500 nm that
would otherwise indicate the presence of ferric-hydroxamate or ferric-catecholate
moieties in these siderophores. This further suggests that these two siderophores belong
to the carboxylate class (86-89). This UV/Vis spectral data was reinforced when both
ferric-staphyloferrin A and ferric-staphyloferrin B were observed to produce a 330 nm
charge transfer band which is indicative of carboxylate siderophores (86-89).
Staphyloferrin A was the first staphylococcal siderophore identified and purified from the
culture supernatants of iron-starved S. hyicus using a series of size-exclusion and anion
exchange HPLC (preparative) in combination with lyophilization techniques (89).
Infrared spectroscopy revealed that the purified siderophore contained hydroxy,
carboxylic acid, and amide groups. Further structural elucidation of staphyloferrin A was
performed through a combination of acid hydrolysis, amino acid analysis, thin-layer
chromatography, mass spectrometry and proton-nuclear magnetic resonance techniques.
Through these experiments, the structure of staphyloferrin A was found to fundamentally
consist of two citrate molecules and a D-omithine amino acid (86). In this case, each

34

nitrogen atom of the D-omithine molecule is connected to one of the prochiral carboxylic
acid groups of citrate to form an amide bond. Mass spectrometry of purified
staphyloferrin A revealed a molecular weight of 480 Da which agrees with the chemical
elucidation experiments (86,89). Staphyloferrin A has been identified in many
staphylococcal species (89).
Meanwhile staphyloferrin B, although initially detected as an accompanying
siderophore with staphyloferrin A, actually proved to be more difficult to study due to
acid stability issues during HPLC purification (86-89). However, this was overcome by
slight modifications to the staphyloferrin A purification protocol (88). Structural
elucidation of staphyloferrin B using the same techniques as for staphyloferrin A revealed
that this second staphylococcal siderophore contained diaminopropionic acid, citric acid,
diaminoethane, and a-ketoglutaratic acid as fundamental components (87,88). Mass
spectrometry of staphyloferrin B suggested that it had a molecular weight of 448 Da,
which agreed with the mass of the condensation product from the acid-hydrolyzed
components (87,88).
It is also worthy to note that initial siderophore screening assays failed to detect
the presence of hydroxamate (via Csaky test) or catecholate siderophores (via Amow test)
in culture supernatants of S. hyicus (89). Furthermore, these initial tests were used to
confirm the lack of catecholate or hydroxamate functional groups on staphyloferrin A and
staphyloferrin B. However, it remains interesting that Courcol et al. (1997) were able to
use mass spectrometry to detect a potential siderophore molecule in culture supernatants
and they tentatively named it “aureochelin”. Preliminary NMR studies by this group
suggested that this compound does indeed contain catecholate-phenolate groups.
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Unfortunately, no further studies have yet been performed on this molecule to confirm
that it is indeed a siderophore.
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Figure 1.5. Chemical structures of staphyloferrin A and staphyloferrin B. Top
structure is staphyloferrin A which consists of two units of citric acid that are each amidelinked (at one of the prochiral carbons of citric acid) to one of the nitrogen atoms of D
omithine. Bottom structure is staphyloferrin B which consists of L-2,-3-diaminopropionic
acid, citric acid, ethylenediamine, and a-ketoglutarate that are successively joined
together via amide bonds.
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Almost a decade after their discovery, genetic and biochemical studies have been
performed to understand the synthesis of the staphyloferrins. These included
identification of the staphyloferrin A biosynthetic and transport gene clusters which are
annotated as sfa and hts, respectively (90,91). Similarly, the staphyloferrin B biosynthetic
and transport opérons have been identified and named sbn and sir, respectively (92) (see
Figure 1.6). More details on the transport and biosynthesis of the staphyloferrins will be
presented in Sections 1.3.5 and 1.4.5.

1.3.5

Siderophore-iron transport in S. aureus

Four siderophore-iron transport systems have been characterized in S. aureus. The
HtsABC (91,93) and SirABC (92,94,95) transport systems function to import the
endogenous S. aureus a-hydroxycarboxylate siderophores staphyloferrin A and
staphyloferrin B, respectively. The remaining two transport systems are the FhuBGC2 D1/D2 (96-99) and the SstABCD (100,101) transport systems involved in ironhydroxamate siderophore and catechol siderophore transport, respectively. The latter two
systems are less relevant to the scope of this thesis and thus will not be introduced further.
Experimental proof that the SirABC system is responsible for transport of
staphyloferrin B stemmed from the observation that deletion of the sirA, sirB, or the
entire sirABC operon resulted in a growth defect of S. aureus in iron-restricted trisminimal-succinate (TMS) medium (97) and that supplementation with staphyloferrin B
(in culture supernatants) failed to rescue the growth of these mutants compared to wild
type (94,95,102). Only recently was the S. aureus HtsABC system (not to be confused
with the S. pyogenes HtsABC system mentioned earlier) proven to transport

1
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Figure 1.6. The hts-sfa and sir-sbn gene clusters responsible for the biosynthesis and
transport of staphyloferrin A and staphyloferrin B, respectively. Shown are the genes
encoding the proteins responsible for the biosynthesis and transport of each siderophore.
The genes of each transport system are adjacent and transcribed divergently from the
biosynthetic gene cluster. Each gene is colour coded according to their predicted protein
products.
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staphyloferrin A (91,93,101) rather than its previously implicated role in heme transport
for S. aureus (103). Unlike the S. aureus sir mutant derivatives, the S. aureus htsABC
mutants showed no growth defect compared to the wild-type strain when grown in a
liquid iron-restricted medium consisting of a 60:40 ratio of horse serum to tris-minimalsuccinate (to mimic host conditions) (91), presumably because the ability to transport
staphyloferrin B compensated for the lack of staphyloferrin A transport. However, a
growth defect was observed when both htsABC and sirABC operons were deleted which
presumably lead to a complete lack of endogenous siderophore transport.
High-resolution crystal structures of both SirA and HtsA receptor lipoproteins
have been recently reported in complex with their corresponding siderophore ligands
(93,95). Structural data reveal that both proteins belong to the class III binding protein
family which is composed of similar N- and C-terminal domains that are connected by a
single a-helical bridge that spans the entire width of the protein. Each domain of the
receptor consists of a parallel beta sheet surrounded by short a-helical segments (93,95).
Bioinformatic analysis and comparisons with structural databases show that the proteins
with highest structural similarity to HtsA and SirA are either Gram-negative periplasmic
binding proteins or lipoproteins such as IsdE (described earlier). When not bound to iron,
staphyloferrin A contains an overall net charge of -5 while staphyloferrin B contains an
overall net charge of -3 (93,95). Binding of iron to each siderophore neutralizes the net
charge, but local regions of the siderophore remain negatively charged and these will be
neutralized by contact residues within the binding pocket of each receptor. Due to the
greater negative charge of staphyloferrin A, the binding pocket of HtsA contains more
positively charged residues (5 to 6 arginines) that make contact with the siderophore. In
contrast, the weaker negative charge exhibited by staphyloferrin B demands a smaller
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number of positively charged contact residues (3 arginines) and the remaining residues
are polar (asparagine or threonine) along with a few hydrophobic residues (tyrosine and
tryptophan) (93,95). Upon binding to each siderophore, only minor loop movements
occur to bind the siderophore rather than large interdomain hinged movements. These
localized loop movements will form part of the binding pocket for each siderophore and
will also reduce the solvent exposed surface area of each ferric-siderophore (reduced to
23.6% for bound ferric-staphyloferrin B and reduced to 14-30% for bound ferricstaphyloferrin A) (93,95), which effectively entraps the siderophore within the binding
cavity of each receptor. Therefore, siderophore binding to each receptor induces minor
conformational changes that further enhance the overall affinity and specificity for its
ligand.
Although, both staphyloferrin A and staphyloferrin B are a-hydroxycarboxylate
siderophores and have at least citrate as a common moiety, each receptor still
demonstrates great affinity (low nanomolar Ka) and binding specificity for its cognate
siderophore (93,95). Note that this high affinity is also observed for the outer membrane
receptors of Gram-negative transport systems and is reminiscent of cell surface receptors
displaying high affinity for ligands in order to achieve maximum transport efficiency.
Therefore, the specificity of each receptor for its siderophore owes to both the unique
contact residues in the binding pocket as well as distinct conformational changes that
occur upon ligand binding. Both HtsA and SirA possess a pair of extremely conserved
glutamate residues (one residue on each base of the C- and N-terminal domains) that
likely interact with arginine-rich patches on the surface of each transmembrane permease
unit. Furthermore, upon siderophore binding to the receptor, minor conformational
changes occur to reposition and poise these glutatmate residues so that they can form salt-
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bridge contacts with the permease arginine pockets (93,95). These recent structural
studies of HtsA and SirA with their ferric-siderophore ligands reveal the critical factors
that determine siderophore receptor specificity and transport mechanisms for Gram
positive bacteria.

1.3.6

Siderophores at the interface of infection and immunity
It is important to note that not all siderophores display equivalency in terms of

virulence potential. For example, enterobactin from E. coli is generally not considered to
be a virulence factor because this siderophore actually performs poorly at scavenging iron
effectively from mammalian host cells despite its great affinity and chelation ability for
ferric-iron (104). This is also true for the similar siderophore bacillibactin which is a
catecholate-type siderophore produced by Bacillus subtilis (105). The reason behind this
poor iron-scavenging potential of these siderophores is because a component of the host
innate immune system actually prevents these siderophores from fulfilling their duties.
Mammalian hosts will produce a 25 kDa protein called siderocalin that will bind onto
ferric-enterobactin or ferric-bacillibactin with high affinity (105,106). Therefore, this
innate immune protein will bind and intercept these ferric-siderophores before they even
have a chance at reaching the cognate transport systems. Note that siderocalin apparently
only demonstrates affinity for catechol ligands within its large binding calyx (106). In
response, pathogenic strains of E. coli, Salmonella typhimurium, and Bacillus anthracis
will produce “stealth siderophores” that are designed to evade interception by siderocalin
(104,105). E. coli and S. typhimurium will produce the “stealth siderophore” salmochelin,
which is a glycosylated derivative of enterobactin (107,108) while B. anthracis will
produce petrobactin in addition to bacillibactin (109). Due to a combination of steric
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hindrance and the bulky structure of these “stealth siderophores”, siderocalin cannot
easily

bind

ferric-salmochelin

or

ferric-petrobactin.

Therefore,

these

“stealth

siderophores” can be considered as virulence factors because they provide an alternate
route of iron uptake for these pathogens (110-112).

1.4.

Siderophore biosynthesis

1.4.1

Nonribosomal peptide synthesis (NRPS) of siderophores

There are two branches of siderophore biosynthesis in bacteria. The first branch
utilizes non-ribosomal peptide synthetases (NRPS) which are large modular enzyme
platforms that condense units of amino acids and central metabolites or precursors
together to form natural products such as a siderophore. These NRPS machineries are also
known to synthesize antimicrobials in both the natural setting (i.e. in soil bacteria) as well
as in the pharmaceutical setting for antibiotics such as vancomycin and methicillin (113).
The second branch of siderophore biosynthesis relies on NRPS-independent siderophore
(NIS) synthetases which are a completely different family of synthetase enzymes from the
NRPS proteins. The NIS synthetases will be discussed further in the following section
(1.4.2). The mechanisms of siderophore synthesis by NRPS enzymes are very complex
yet elegant. Various NRPS-based siderophore biosynthetic pathways have already been
elucidated or proposed including the siderophores enterobactin, pyochelin, yersiniabactin,
vibriobactin, mycobactin, and anguibactin (for a review see Crosa and Walsh 2002). For
the purpose of providing an example of NRPS siderophore synthesis, only the main points
of enterobactin biosynthesis will be presented here since enterobactin represents the best
studied NRPS siderophore to this day. Enterobactin is synthesized by the gene products
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encoded from the entABCDEF operon in E. coli along with two Substrates: L-serine and
chorismate (an intermediate in aromatic amino acid biosynthesis) (see Figure 1.7).
Biosynthesis is initiated by the three enzymes EntA, EntB, and EntC which work together
to convert the chorismate substrate to 2,3-dihydroxybenzoic acid (2,3-DHB). The next
enzyme, EntE, adenylates (with ATP) the carboxyl group of 2,3-DHB to form an
adenosyl-2-3-DHB intermediate which is now activated for acylation onto a thiol group
of a phosphopantetheine moiety on the C-terminal (thiolation) domain of EntB. This will
form a 2,3-DHB thioester that is covalently joined to EntB. At the same time, much like
chorismate, L-serine is adenylated (with ATP) at the carboxyl group by the adenylation
(A) domain of the main NRPS EntF. This L-serinyl-adenylate intermediate is then
acylated to a thiol group on the thiolation (T) domain of EntF. In effect, this will form an
L-serinyl thioester that is covalently attached to EntF (at the T domain). Next, the
condensation (C) domain of EntF joins the exposed amino group of the L-serinyl thioester
with the 2,3-DHB thioester that is still attached onto EntB. This will free the 2,3-DHB
thioester from EntB and will form the 2,3-DHB-L-serinyl thioester intermediate that is
covalently attached to EntF at the T domain. Next, an active serine residue on the
adjacent thioesterase (TE) domain will attack the thioester linkage of the 2,3-DHB-Lserinyl thioester and this will covalently transfer the intermediate to the TE domain of
EntF. This will form a 2,3-DHB-L-serinyl-TE domain ester. By this time, a second 2,3DHB-L-serinyl thioester would have already assembled back on the T domain of the
same EntF enzyme. The TE domain on EntF will then catalyze the condensation between
the new 2,3-DHB-L-serinyl thioester (on the T domain) with the 2,3-DHB-L-serinyl-TE
domain ester. This will form two-thirds of enterobactin which is essentially a dimer of
2,3-DHB-L-serinyl esters. This dimer remains covalently attached onto the TE domain
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and waits for a third unit of 2,3-DHB-L-serinyl thioester to arrive on the T domain of
EntF so that another round of condensation reaction can occur. Once a trimer of 2,3DHB-L-serinyl esters have formed on the TE domain, a macrocyclization reaction will
occur that is also catalyzed by the TE domain to release the final enterobactin product
from EntF (114,115). The described mechanism is only a brief and simplified overview of
enterobactin biosynthesis and the synthesis of various catecholate siderophores employ a
similar mechanism (114). An important difference between NRPS and NIS synthetases is
that biosynthetic intermediates remain covalently attached to the enzymatic machinery in
the NRPS mode (i.e. steps after initial adenylation and acylation of serine or 2,3-DHB)
whereas biosynthetic intermediates are freely dissociable from NIS synthetases at each
step of the pathway.
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Figure 1.7. Biosynthetic pathway for the model NRPS siderophore enterobactin. The
NRPS pathway for the biosynthesis of enterobactin is shown with the relevant Ent
enzymes as well as the structures of associated biosynthetic substrates and intermediates.
The functional roles of each domain for the Ent enzymes (primarily EntB and EntF) are
coloured and denoted with letters such as “A” for adénylation, “T” for thiolation, “C” for
condensation, and “TE” for thioesterase.
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1.4.2

NRPS-independent synthesis (NIS) of siderophores

In recent years, there has been emerging interest in a new family of biosynthetic
enzymes. Interest stems from their potential applications in biotechnology and
pharmaceuticals, as well as their natural roles in microbial natural product synthesis and
virulence. Unlike NRPS synthetases (see Section 1.4.1), these enzymes do not serve as
large reaction platforms that catalyze multiple reactions with their substrates. Therefore
these enzymatic systems do not resemble or incorporate the use of NRPS synthetases but
they still share the ability to synthesize natural products such as siderophores. Therefore,
the name given to these enzymes are NRPS-independent siderophore (NIS) synthetases.
Initial studies with NIS synthetases began with the biosynthetic machinery involved in
aerobactin biosynthesis (116). This siderophore is readily produced by E. coli, Shigella
spp., Yersinia spp., and Salmonella spp. under conditions of iron starvation and has been
reported as a virulence factor (117). Therefore, aerobactin is regarded as the model
siderophore in the NIS domain of siderophore synthesis much like how enterobactin is the
model NRPS siderophore. The biosynthetic gene cluster for aerobactin exists on a
plasmid (pColV-K30) of E. coli (116) and is annotated as iucABCD. This gene cluster
contains two NIS synthetases which are IucA and IucC. Meanwhile, IucD and IucB are
substrate or precursor modification enzymes and such auxiliary enzymes are commonly
found in siderophore biosynthetic gene clusters that accompany either NIS or NRPS
enzymes. More details about auxiliary enzymes will be discussed in the next section
(1.4.3). At this point, a brief description of the proposed mechanism behind aerobactin
biosynthesis will be presented (Figure 1.8). Note that the enzymes and the pathway for
aerobactin biosynthesis served as the modeling platform for all other NIS siderophore
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biosynthetic pathways solved to this date. First, IucD is a flavin-dependent
monooxygenase that adds a hydroxyl group to the 8-amino group of L-lysine to form N6hydroxy-L-lysine. Next, IucB will take this modified lysine as a substrate and catalyze an
acetyl-transferase reaction onto the e-hydroxylamino group to give rise to the key
precursor A^-acetyl-A^-hydroxy-L-lysine (118,119). Note that the next steps of this
pathway are based on genetic predictions as the actual biochemical characterization of the
aerobactin NIS synthetases have yet to be studied (120,121). The first NIS synthetase
IucA is predicted to condense the a-amino group of /V6-acetyl-vV6-hydroxy-L-lysine onto
one of the prochiral carboxyl groups of citric acid to form the aerobacin intermediate N6acetyl-A^-citryl-A^-hydroxy-L-lysine. The last step is predicted to involve the second NIS
synthetase IucC which condenses the newly formed intermediate with a second molecule
of A^-acetyl-A^-hydroxy-L-lysine to form aerobactin (120,121). Although unknown at the
time, IucA and IucC were predicted to utilize a certain nucleotide triphosphate (NTP) in
order to couple the energy released from NTP hydrolysis to drive the reaction towards a
more thermodynamically and kinetically favourable direction (115,122). The likely NTP
to do this job would be ATP for activating the carboxyl groups on substrates such as citric
acid (122), however the NTP specificity for IucA and IucC has yet to be determined.
Soon after the discovery of aerobactin and its associated biosynthetic gene cluster,
genetic studies revealed various siderophore biosynthetic gene clusters that contain
enzymes with homology to the archetypical NIS synthetases IucA and IucC (122). With
the help of bioinformatics and phylogenetic analysis, NIS synthetases have been grouped
into three major classes as follows: type A, type B, and type C (114,122). Where a known
siderophore structure can be associated with a gene cluster, accurate predictions can be
made regarding how each biosynthetic enzyme may contribute to the overall pathway of
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siderophore synthesis. Therefore, a trend was established with regards to each type of NIS
synthetase and its substrate specificity (115,122). The type A NIS synthetases which bear
homology with its archetype enzyme IucA is known to recognize citric acid as the
carboxylate substrate and will catalyze an amide (or ester) condensation between one of
the prochiral carboxylates of citrate with an amino or alcohol nucleophile (115,122). The
type B NIS synthetases actually bear no homology to a model enzyme since the iuc gene
cluster does not possess an enzyme of this type. However, type B enzymes have been
predicted to recognize a-ketoglutarate as the carboxylic acid substrate and will catalyze
an amide (or ester) bond formation between an amine- or hydroxyl-containing molecule
with the C5 carboxyl group on a-ketoglutarate (115,122). Lastly, type C enzymes share
similarity with the archetype NIS synthetase IucC and will catalyze amide bond
formations between an amine substrate with a monoamide or monoester derivative of
citric acid (or succinic acid) as the carboxylate substrate (115,122). Note that in all cases,
the carboxylate substrate for NIS synthetases are always either citric acid, a-ketoglutarate,
or a citric acid (or succinic acid) monoester/monoamide. However, the identity of the
amine or alcohol nucleophillic substrate is more uncertain and often cannot be easily
predicted from studying the siderophore structure itself since these substrates are prone to
modification by auxiliary enzymes (Section 1.4.3). Recently, it was found that type B
synthetases actually branch off into a new subfamily of synthetases. Traditionally, the
type B subfamily consists of enzymes that recognize a-ketoglutarate as a substrate (as
described above) but the new subfamily actually recognizes citrate as a substrate instead
(90,115). Therefore, this subfamily has been formally dubbed type A’ synthetases
because they recognize citrate as the carboxylate substrate, but are more phylogenetically
related to type B synthetases (90,115). The only type A’ enzymes characterized to date
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are those involved in staphyloferrin A biosynthesis (more details in Section 1.4.4.). Note
that within the same NIS synthetase type, enzymes can perform either a single modular
reaction (two substrates with the formation of one product) or multiple “iterative”
reactions (the product of the one reaction becomes a substrate of the next reaction by the
same enzyme) (115). In this manner, NIS synthetases from various organisms have given
rise to the following known siderophores: aerobactin, achromobactin, alcaligin,
desferrioxamine E, vibrioferrin, rhizobactin, rhizoferrin, petrobactin, and staphyloferrins
A and B (115,122).
Another model NIS siderophore that has received much attention recently is
achromobactin which is synthesized by the plant pathogen Dickeya dadantii (123). The
siderophore is a condensation product of citrate, ethanolamine (derived from serine),
diaminobutyrate, and two units of a-ketoglutarate (124). The achromobactin biosynthetic
gene cluster (acs) is contains three NIS synthetases AcsA, AcsC, and AcsD which are
type B, type C, and type A enzymes, respectively along with several auxiliary enzymes to
support precursor biosynthesis/intermediate modification (124). The biosynthetic pathway
for the siderophore has also been recently characterized using purified enzymes and mass
spectrometry experiments (124). Due to the presence of all three classes of synthetases in
the acs gene cluster (unlike aerobactin which only contains two synthetases), the
achromobactin biosynthetic system represents an ideal complete model to study NIS
synthetases and the reaction mechanisms that they catalyze.
Furthermore, the crystal structure of AcsD represents the first structure of any NIS
synthetase solved (125). The holo-structure of AcsD (containing citrate-ATP-Mg2+
complex) revealed that citrate in the active site was positioned such that one of its
prochiral carboxyl groups is poised to attack the a-phosphate of ATP and displace a
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diphosphate (resulting in AMP) via an SN2-type reaction (125). The resolution of such a
reaction would form a hallmark acyl-adenylate intermediate of NIS synthetases as this
intermediate would be subsequently attacked by an amine or alcohol nucleophile within
the same active site to form a siderophore intermediate or the siderophore itself (125). In
the case of AcsD, L-serine serves as the most favourable alcohol nucleophile that will
attack the acyl-adenylate intermediate and displace AMP to form the citryl-L-serine
intermediate of achromobactin (125). As mentioned earlier, the major difference between
NRPS and NIS mechanisms is the lack of any enzyme-intermediate tethering in NIS
synthesis compared to NRPS mechanisms (see enterobactin biosynthesis in Section
1.4.1.), since NIS synthesis permits dissociation between enzymes and biosynthetic
intermediates at each step along the pathway.
Lastly, hybrid NIS-NRPS siderophore biosynthetic systems also exist and
petrobactin (from B. anthracis) represents the only known siderophore synthesized in this
manner. Petrobactin is composed of two units of 3,4-dihydroxybenzoic acid, two units of
spermidine, and one unit of citric acid (126). The siderophore is synthesized by enzymes
encoded from the asbABCDEF operon (126,127). The genes asbA and asbB encode type
A and type C NIS synthetases, respectively, while asbCDE encode an NRPS-like system.
The biosynthetic pathway for petrobactin biosynthesis has been characterized (126,127)
and it elegantly incorporates NIS and NRPS elements as introduced earlier. Briefly,
condensation of the citrate prochiral carboxyl groups with spermidine residues is an NISdependent process and the capping of the citryl-spermidine primary amine groups with
3,4-dihydroxybenzoic acid is achieved through NRPS mechanisms (127).
The main engines of siderophore biosynthesis are the synthetases (NRPS or NIS),
but there are often other enzymes encoded within a biosynthetic gene cluster that are
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needed to synthesize, modify, or tailor certain substrates/precursors such that the resulting
products can become suitable substrates for downstream siderophore synthetases. The
next section will discuss how these auxiliary enzymes are involved in siderophore
biosynthesis.
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Figure 1.8. Biosynthetic pathway for the model NIS siderophore aerobactin. The NTS
synthetase pathway for the biosynthesis of aerobactin is shown with chemical structures
of substrates and biosynthetic intermediates. This proposed pathway for the synthesis of
aerobactin utilizes two auxiliary enzymes (IucB and IucD) to modify L-lysine such that it
becomes a recognizable substrate for the NIS synthetases IucA and IucC to condense onto
citric acid. The identity of the nucleotide cofactor has not been experimentally identified
but is most likely ATP based on studies involving other NIS synthetases.
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1.4.3

Auxiliary enzymes of siderophore biosynthesis

Due to the structural and chemical diversity of siderophores, one can envision that
certain siderophore precursors or synthetase substrates may not be easily obtainable by
the organism (i.e. under conditions of iron starvation) or may not be a naturally occurring
cellular metabolite. Therefore, siderophore biosynthetic systems may contain enzymes
that can modify existing cellular metabolites such as amino acids in order to incorporate
them into the siderophore structure. Recent studies have only focused on the main
siderophore synthetases, while less experimental attention has been provided to these
auxiliary enzymes. The enterobactin biosynthesis enzymes EntA, EntB, EntE, and EntC
can be considered auxiliary enzymes that are responsible for converting the aromatic
amino acid intermediate chorismate into 2,3-dihydroxybenzoic acid and activating it for
reaction with the NRPS platform (EntF). Similarly, the enzymes IucD (flavin-dependent
monooxygenase) and IucB (acetyltransferase) from aerobactin biosynthesis modify Llysine so that it becomes a substrate for the NIS synthetases (118,119). In this case, the
acetylation and hydroxylation of L-lysine equips aerobactin with a total of four iron
coordinating oxygen atoms which underscores the importance of these auxiliary enzymes
for aerobactin biosynthesis because they provide both structural and iron coordinating
moieties of the siderophore. Furthermore, auxiliary enzymes also exist for other
siderophore biosynthetic systems such as alcaligin (ale) which utilizes a PLP-dependent
ornithine decarboxylase (unclustered with the ale operon), two monooxygenases (AlcA
and AlcE), and an acetyltransferase (AlcB) (122). Meanwhile, vibrioferrin biosynthesis
(pvs) also employs a PLP-dependent decarboxylase (PvsE), as well as a unique enzyme
(PvsA) with similarity to D-ala-D-ala ligases involved in cell wall biosynthesis, which is
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presumably used to link two consecutive amino acids together in the siderophore structure
(122). As for the staphyloferrins, a putative alanine racemase (SfaC) exists in the sfa gene
cluster for staphyloferrin A biosynthesis and although it has not been biochemically
investigated, it is reasonable to assume that this enzyme enantiomerizes L-omithine into
D-omithine which would become the amine nucleophile for the NIS synthetases (90).
Meanwhile, the sbn operon responsible for staphyloferrin B biosynthesis encodes
four auxiliary enzymes such as a putative ornithine cyclodeaminase (SbnB), a putative Oacetyl-L-serine sulfhydrylase (SbnA), a carbohydrate aldolase (SbnG), and a PLPdependent amino acid decarboxylase (SbnH), which are all presumed to be involved with
staphyloferrin B precursor formation or intermediate modification. The function of some
of these auxiliary enzymes for staphyloferrin B biosynthesis will also be investigated in
this thesis (Chapters 2 and 3). Similarly, the achromobactin biosynthetic gene cluster acr
contains a PLP-dependent amino acid decarboxylase (AcsE), an aldolase (AcsB), and an
aminotransferase (AcsF) (124). For achromobactin, it has been proposed that the
decarboxylase removes carbon dioxide from L-serine to generate the ethanolamine
portion of achromobactin and the aminotransferase is responsible for generating the
diaminobutyrate portion (122,124). Note that there has not yet been a proposed function
for the aldolase in both staphyloferrin B or achromobactin biosynthesis at least until
Chapter 3 of this work. At this point, it appears that certain auxiliary enzymes are more
common across different siderophore biosynthetic operons whereas others are more
specialized for a particular pathway. The existence of similar auxiliary enzymes between
two or more biosynthetic clusters may be an indicator of similar biosynthetic pathways
leading to structurally similar siderophores as in the case of staphyloferrin B and
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achromobactin. Therefore in order for complete elucidation of a biosynthetic pathway,
characterization of the function of these auxiliary enzymes cannot be overlooked.

1.4.4

Siderophore Biosynthesis in S. aureus

As mentioned previously, S. aureus is known to produce two siderophores named
staphyloferrin A and staphyloferrin B through enzymes encoded by the sfa and sbn gene
clusters, respectively. The original staphyloferrin studies by Haag et al. (1994) detected
the presence of staphyloferrin A from the culture supernatants of all staphylococcal
species tested when grown under iron-restricted conditions. Interestingly, Haag et al.
(1994) were unable to detect significant staphyloferrin B levels from coagulase-negative
staphylococci, but were able to detect the presence of staphyloferrin B in several
coagulase-positive staphylococci other than S. aureus, including S. hyicus and S.
intermedius. However, no follow-up study has since been performed to biochemically or
genetically confirm the fact that S. hyicus and S. intermedius do indeed produce
staphyloferrin B. Recently, the genome of coagulase-positive S. pseudintermedius has
been completed and it was found to encode the sbn operon as well as the sir operon for
staphyloferrin B biosynthesis and transport. Although S. pseudintermedius was not
originally screened for siderophore production by Haag et al. (1994), it is peculiar that
staphyloferrin B production is tightly associated with coagulase-positive staphylococci.
Very recently, two studies proved that the sfa gene cluster was responsible for
staphyloferrin A biosynthesis. Cotton et al. (2009) reconstituted the staphyloferrin A
biosynthetic pathway in vitro and demonstrated that two purified Type A’ NIS enzymes
SfaB and SfaD were required to sequentially condense two molecules of citrate onto a D-
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ornithine amino acid. Each NIS synthetase recognizes citrate as a substrate in order to
condense one prochiral carboxyl group from each citrate molecule onto one of the amino
groups of D-omithine (90). Meanwhile, genetic studies performed by Beasley et al.
(2009) showed that an S. aureus sfa mutant did not display any phenotypic difference
compared to the isogenic wild-type when grown in iron-restricted medium containing
serum (mammal or human) (91,101). Despite the lack of phenotype, mass spectrometry
showed that culture supernatants derived from the S. aureus sfa mutant lacked the
presence of staphyloferrin A (91). However, pairing the sfa mutation with an sbn whole
operon deletion resulted in a severe growth deficit versus wild-type, presumably due to
the complete loss of siderophore production (91,101). On the contrary, the S. aureus sbn
mutant does in fact show a growth deficit compared to wild-type (and the sfa mutant) in
iron-restricted medium containing serum and this mutant growth phenotype is described
as an exaggerated lag phase (91,101). It is therefore tempting to suggest that
staphyloferrin B is the more dominant siderophore for iron transport in serum. However,
when holotransferrin was provided as the sole iron source, both siderophores performed
equally well in acquiring iron and the lack of any one siderophore biosynthetic system
could be compensated by the presence of the other (101). Therefore, Beasley et al. (2011)
attributed this observation to a potential serum factor that inhibits the iron-scavenging
potential of staphyloferrin A.
The experimental validation that the sbn operon in S. aureus is responsible for
staphyloferrin B production is a major component of this thesis. However, a quick survey
of the sbn operon already indicates that the biosynthetic pathway for this siderophore
would be much more complex than the characterized biosynthetic pathway for
staphyloferrin A. The sbn operon was first studied by Dale et al. (2004) and at that time
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the identity of the siderophore produced was inconclusive, mainly because little
knowledge existed at the time regarding NIS synthetases. Interestingly though, deletion of
an sbn NIS synthetase gene attenuated the virulence of S. aureus in a mouse model of
kidney infection (92). This finding supported the notion that iron acquisition mechanisms
(including siderophore synthetases) are indeed virulence factors. In the same year, a study
by Bhatt and Denny (2004) showed that a homologous siderophore biosynthetic operon in
Ralstonia solanacearum was responsible for producing staphyloferrin B as it was
identified using mass spectrometry of culture supernatants. This study gave support to the
hypothesis that perhaps the sbn operon in S. aureus was also responsible for
staphyloferrin B production (128). Furthermore, the sbn operon is predicted to encode
three NIS synthetases SbnE, SbnC, and SbnF that correspond to a type A, type B, and
type C synthetase, respectively, and are transcriptionally accompanied by at least four
auxiliary enzymes. The predicted functions of the Sbn enzymes also agree well with the
elucidated structure of staphyloferrin B. Therefore, reconstitution of the staphyloferrin B
biosynthetic pathway will be presented in the next chapter (Chapter 2) of this thesis.
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1.5. Research hypothesis and objectives

The hypothesis for the research project detailed in this thesis is as follows: the
enzymes encoded by the sbn operon are both necessary and sufficient to generate
staphyloferrin B.
In order to test the above hypothesis, I will tackle four objectives. The first
objective is to overexpress and purify all staphyloferrin B synthetases and auxiliary
enzymes. This can be achieved through large-scale and rapid purification protocols in
order to obtain adequate amounts of purified enzyme from the cytoplasm of E. coli.
Meanwhile, the second objective is to define substrates, products, and reaction
conditions for each of the staphyloferrin B synthetases (i.e. SbnC, SbnE, SbnF).
Spectrophotometric or chemical assays as well as mass spectrometry experiments will
allow detection of the activity and products of these siderophore synthetases, respectively.
Much like the second objective, the third objective focuses on defining the
substrates, products, and reaction conditions for auxiliary enzymes involved in
staphyloferrin B precursor formation (i.e. SbnA, SbnB, SbnG, SbnH). Once again,
spectrophotometric or chemical assays coupled with mass spectrometry will allow
detection of the activity and products of these auxiliary enzymes, respectively.
Finally, the fourth objective is to study the interaction between in vitro prepared
ferric- staphyloferrin B with the purified cognate receptor protein SirA. These
experiments will allow for the characterization of the receptor protein’s affinity for the
ferrated siderophore.
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2.1. Introduction
Iron is an essential, yet limiting, nutrient for virtually all organisms. Iron
limitation frequently results from iron existing in the oxidized ferric (Fe3+) form which
then reacts with oxygen to form hydroxide and oxyhydroxide precipitates (1). Bacteria
have evolved several means by which to secure iron but, by far, the most common
strategy invokes the use of small molecules termed siderophores. Siderophores are lowmolecular-weight compounds made of both amino acids and non-proteogenic amino acids
(2). Different types of siderophores exist depending on functional groups involved in iron
co-ordination. Siderophores can be synthesized by modular enzymatic platforms called
non-ribosomal peptide synthetases (NRPS) which synthesize siderophores using protein
carrier-linked intermediates (for a review, see (3)). The best-characterized NRPSdependent siderophore is enterobactin. Another enzymatic route to siderophore synthesis
is through the NRPS-independent siderophore (NIS) synthetase system which utilizes
condensation reactions with units of dicarboxylic acids, diamines and/or amine alcohols
to form the final siderophore structure (4). This biosynthetic method differs from the
NRPS system in that intermediates and enzymes are freely dissociable from one another
during assembly. Aerobactin, produced from Escherichia coli, represents the model NIS.
Its biosynthesis utilizes two siderophore synthetases, IucA and IucC, to condense two
molecules of N6-acetyl-A^-hydroxylysine to a citrate molecule (5). Due to advances in
bioinformatics and microbial genome sequencing, knowledge of NIS systems has
expanded tremendously; NIS systems are present in over 40 bacterial species.
In brief, the mechanism of NIS synthetases begins with the ATP-dependent,
enzymatic adenylation of a carboxylic acid to form an enzyme-linked acyl-adenylate
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(4,6). The intermediate thus formed is reactive and prone to an addition-elimination
reaction with a second substrate containing a nucleophilic amino or hydroxyl group to
form an ester or amide. A model, based on the characterized functions of IucA and IucC,
has been put forth to categorize NIS synthetases into three distinct classes named type A,
B and C; the model proposes that each type of synthetase will recognize a certain
carboxylic acid substrate along with an additional amine or alcohol substrate (4). By
definition, type A synthetases will catalyse formation of an amide (or ester) bond between
an amino or hydroxyl group containing substrate and one of the two prochiral carboxylic
acids of citrate. Type B synthetases are thought to recognize the C5 carboxyl portion of aketoglutarate (a-KG) and will condense it to amino or hydroxyl functional groups on a
second substrate to form amide or ester bonds respectively. Lastly, type C synthetases
will catalyse the amide or ester bond formation between a substrate with an amino or
hydroxyl group with a second substrate which is already a monoamide or monoester that
still has a free prochiral carboxyl group.
Staphylococcus aureus is a notorious Gram-positive bacterial pathogen. It is the
causative agent of a large number of maladies, ranging from impetigo and skin abscesses
to more serious infections including pneumonia, food poisoning, endocarditis, meningitis,
toxic shock and septicaemia. Members of the staphylococci produce two structurally
characterized polycarboxylate-type siderophores called staphyloferrin A (SA) and
staphyloferrin B (SB) (7-10). Production of SA, composed of d-omithine and two
molecules of citrate, requires the activity of the sfa gene products (11,12). Synthesis of
the 8-citryl-d-omithine intermediate requires SfaD whereas condensation of this
intermediate to another molecule of citrate to produce the final siderophore structure is
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carried out by the activity of SfaB (12). It is presumed that in the cell, d-omithine is
produced by the activity of a putative ornithine racemase (SfaC).
Staphylococcus aureus possesses a second genetic locus (sbnA-I) responsible for
siderophore production. Insertional inactivation of sbnE or deletion of the entire ninegene sbn operon eliminates production of a siderophore and results in decreased growth
in iron-starved media (11,13). In S. aureus, the locus has not yet been linked to synthesis
of a particular structurally characterized siderophore but deletion of a homologous locus
in Ralstonia spp. resulted in loss of SB in iron-starved culture supernatants (14), lending
support to the hypothesis that sbn in S. aureus is responsible for production of SB.
Synthesis of SB, which contains 1-2,3-diaminopropionic acid (Dap), citrate, 1,2diaminoethane (Dae) and a-KG (9), is predicted to require the activity of three NIS
synthetase enzymes to condense these substrates. The sbn gene locus encodes three such
NIS synthetases, SbnE, SbnC and SbnF, which are classified as type A, type B and type C
siderophore synthetases respectively. Thus, it was reasonable to assume that SB synthesis
required the products of the sbn gene locus.
Herein, we report the first molecular and biochemical characterization of SB
biosynthesis. We show that production of SB in iron-starved culture supernatants of
S. aureus is dependent on the presence of the sbn locus. Sbn enzymes were
overexpressed, purified and characterized for their specific activity. The results
demonstrate that the minimal SB synthetase consists of SbnCEF, with the added
requirement of the decarboxylase enzyme SbnH. Accordingly, substrate specificity and
electrospray ionization-mass spectrometry (ESI-MS) analysis of these enzymes and their
reaction products allow us to propose for the first time the biosynthetic pathway for the
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siderophore. We further demonstrate that SB, synthesized in vitro, is able to fulfill the
iron needs of S. aureus in a SirABC transporter-dependent manner.

2.2. Experimental procedures
2.2.1. Bacterial strains, plasmids, and standard growth conditions
Bacterial strains and plasmids used in this study are described in Table 2.1. E. coli
were grown in Luria-Bertani broth (Difco). For experiments not directly involved in the
analysis of iron uptake, S. aureus were grown in tryptic soy broth (Difco). Tris-minimal
succinate (TMS) was prepared as described (15) and used as an iron-limited minimal
medium. To further restrict the level of free iron in TMS, the iron-chelating compounds
2,2'-dipyridyl and ethylene diamine-di(o-hydroxyphenol acetic acid) (EDDHA) were
added as indicated in the text. Where necessary, kanamycin (30 pg ml-1) was
incorporated into media for the growth of E. coli strains. For S. aureus, kanamycin
(50 pg m l 1), neomycin (50 pg m l 1) and tetracycline (4 pg m l 1) were incorporated into
growth media as required. Solid media were obtained by the addition of 1.5% (w/v) Bacto
agar (Difco). All bacterial growth was conducted at 37°C unless otherwise stated. Ironfree water for preparation of growth media and solutions was obtained by passage
through a Milli-Q water filtration system (Millipore Corp.).

2.2.2. Recombinant DNA methodology
Standard DNA manipulations were performed essentially as described (19).
Restriction endonucleases and DNA-modifying enzymes were purchased from Roche
Diagnostics (Laval, Quebec, Canada), New England Biolabs (Mississauga, Ontario,
Canada), Life Technologies (Burlington, Ontario, Canada) and MBI Fermentas
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(Flamborough, Ontario, Canada). Plasmid DNA was purified using QIAprep plasmid spin
columns (QIAgen, Santa Clarita, California) as described by the manufacturer.
Polymerase chain reactions were performed using Pwol DNA polymerase (Roche
Diagnostics).

2.2.3 Siderophore plate bioassays
Siderophore plate bioassays were performed as described (11). Growth promotion,
as measured by the diameter of the growth halo around each disk, was determined after
36 h incubation at 37°C.
2.2.4. Bacterial growth curves
Bacteria were cultured for 12 h in TMS broth then 12 h in TMS broth containing
100 pM 2,2'-dipyridyl (Sigma-Aldrich). Cells were washed twice in saline, and diluted
1:100 into 60% horse serum (Sigma-Aldrich)-40% TMS broth. For iron-replete media,
50 pM FeCb was included. Cultures were grown under constant, medium-amplitude
shaking in a Bioscreen C machine (Growth Curves, USA). Optical density was measured
at 600 nm every 30 min. However, for clarity of growth curve figures, data are shown
only at 2 h intervals.
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Table 2.1.

Bacterial strains, plasmids and oligonucleotides used in this study.

Oligonucleotides containing relevant restriction endonuclease cut sites for cloning into
pET28a(+) are underlined in the table.
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Bacterial
strains,
plasmids,
and primers
E. coli
DH5a

ER2566

BL21(DE3)
S. aureus
RN4220
RN6390
H306
HI 324
H1661
HI 649
HI 448
H1480
Plasmids
pET28a(+)
pSbnC
pSbnE
pSbnF
pSbnH
pSirA
Primers
SbnC
SbnC
(Reverse)
SbnE
SbnE
(Reverse)
SbnF
SbnF
(Reverse)
SbnH
SbnH
(Reverse)

Description3

Source or
reference

F’ (j)80d/acZAM15 recAl endAl nupG gyrA96glnV44 thi-\
hsdR17(r\E m / ) X supE44 relAl deoR
E(lacZYA-argF)\] 169
F' X fhuA2 [Ion] ompTlacZv.Tl gene 1 galsulA ll
\{mcrC-mrr)\ 14::IS/0 R(wcr-73::miniTn/0-Tets)2
R(zgZ>-21O::Tn70)l (Tets) endAl [dcm]
F ompT gal dcm Ion hsdSe (rs’ mg') X(DE3 [lad lacUVST7 gene 1 indl sam7 nin5])
rK" mK+; accepts foreign DNA
Prophage-cured wild type strain
RN6390 sirA; KmR
RN6390 Ax/w;TetR
RN6390 Asfa; KmR
RN6390 Asbn Asfa- TetR KmR
RN6390 Ahts; TetR
RN6390 sirA Ahts; TetR KmR

Promega

New
England
Biolabs
Novagen

(16)
(17)
(18)
(11)
(11)
(ID
(11)
(11)

Overexpression vector for hexahistidine-tagged proteins;
KmR
pET28a(+) derivative encoding SbnC; KmR
pET28a(+) derivative encoding SbnE; KmR
pET28a(+) derivative encoding SbnF; KmR
pET28a(+) derivative encoding SbnH; KmR
pET28a(+) derivative encoding SirA (no lipobox); KmR

Novagen

5 ’-T T G A G A T C T A G A T T G C A G A A T C A T A C A G C A G T C A -3 ’

This study
This study

This study
This study
This study
This study
(22)

5 ’- T T G A T A G G A T C C C T A T A A A C T G A C T G A G C C A T A A -3 ’

’

5’-T T G A T A G G A T C C T G G T G C A T C A C T C T A G T C T T T -3 ’

This study
This study

5’-T T G A T A G C T A G C G T G A A T C A A A C A A T T C T T A A T C G -3 ’
5 -T T G A T A G G A T C C T C C G G T A T A G A A T T A A A A A T G C -3 ’

This study
This study

5

T T G A G A G C T A G C G T G C A A A A T A A A G A A T T A A T A C -3

5 ’-T T G A T A G C T A G C A T G C G T A T A G T T C A A C C T G T T A -3

5’-T T G A T A G G A T C C G T T A T T C A T C C T C C T T T G T T T -3 ’

’

This study
This study
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2.2.5. Siderophore detection
To measure levels of siderophore activity, chrome azurol S (CAS) shuttle solution
(20) was prepared. In the case of in vitro synthesized SB, 50 pi of the reaction mixture
was removed and diluted in 450 pi of deionized water followed by 500 pi of CAS shuttle
solution in a 1 ml spectrophotometer cuvette. The mixture was then incubated in the dark
for 45 min. Siderophore quantification and absorbance readings (at 630 nm) were
performed as described (11).
2.2.6. Protein overexpression and purification
Proteins were expressed in E. coli BL21(DE3) by cloning the coding regions,
amplified from the genome of S. aureus Newman, into pET28a(+). E. coli cells
containing expression constructs were grown to mid-log phase at 37°C with aeration
before IPTG (isopropyl-P-d-thiogalactopyranoside) (0.5 mM) was added, and cells
cultured for an additional 16 h at room temperature. The cells were re-suspended in
50 mM HEPES buffer (pH 7.4), 500 mM NaCl, 10 mM imidazole and lysed in a French
pressure cell at 10 000 psi, and the lysate was centrifuged at 15 000 x g for 15 min to
remove unbroken cells and debris, prior to centrifugation at 150 000 x g for 60 min to
remove insoluble material. The soluble sample was applied to a 1 ml HisTrap nickel
affinity (GE Healthcare) column equilibrated with buffer A and the 6xHis-tagged proteins
were eluted from the column with a gradient of 0-80% buffer B over 20 column volumes;
buffer A contained 50 mM HEPES buffer (pH 7.4), 500 mM NaCl, lOmM imidazole,
and buffer B contained 50 mM HEPES buffer (pH 7.4), 500 mM NaCl, 500 mM
imidazole. Proteins were dialysed into 50 mM HEPES (pH 7.4), 150 mM NaCl and 10%
glycerol at 4°C. Protein purity was confirmed using ESI-MS and sodium dodecyl
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sulphate-polyacrylamide gel electrophoresis (19). Protein yield from the induced cultures
harbouring the expression constructs was determined to be 3 mg 1_1 (SbnC), 3 mg l“1
(SbnE), 3 mg F 1(SbnF), 17 mg F 1(SbnH), and 25 mg F 1(SirA).
2.2.7. Mass spectrometry
LC-MS and LC-MS/MS analyses of concentrated culture supernatant samples
were performed as described previously (11).
For analysis of in vitro reaction products, enzymes were first removed using
centricon with molecular weight cut-off of 10 000 Da. Effluent was injected onto the LCMS/MS system, consisting of a Waters CapLC with a Phenomenex Jupiter Proteo 90 A
column (150 x 1.0 mm, 4 pm) coupled to a Q-TOF (micro, Waters) mass spectrometer.
Separation was carried out at a flow rate of 40 pi min 1 with a gradient starting at 1% B
and increase to 50% B in 15 min and then to 95% B in 5 min, and hold for 5 min. Solvent
A was water and solvent B was 95% acetonitrile, both with 0.1% formic acid. LC-ESF
MS analysis was performed in negative ion mode with a scan range of 200-700 m/z.
Collision-induced dissociation was performed with a mass range of 60-500 m/z using
argon as the collision gas. Variable collision energy of 20-30 V was applied to obtain an
informative fragmentation spectrum. Data were acquired and analysed by MassLynx 4.0
(Micromass).
2.2.8 In vitro staphyloferrin B biosynthesis
Reactions, in a total volume of 100 pi, consisted of 5 mM ATP, 0.5 mM MgCF,
0.5 mM pyridoxal-5'-phosphate, 1 mM Dap HC1, 1 mM sodium citrate, 1 mM a-KG,
5 pM SbnC, 5 pM SbnE, 5 pM SbnF, 5 pM SbnH and was buffered in 50 mM HEPES
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pH 7.4. HEPES was replaced with 50 mM phosphate buffer pH 7.4 for some reactions
where ion species from HEPES interfered with detection of a SB intermediate at m/z 235.
When assessing the ability of Dae to substitute the need for SbnH, 1 mM Dae was added
to replace the SbnH and pyridoxal-5'-phosphate components of the above reaction
mixture. Reactions were incubated overnight at room temperature in the dark. The
complete reaction resulted in the production of 1 nM Desferal™ equivalents as
determined using the CAS siderophore detection assay.
2.2.9. Substrate selectivity (hydroxamate formation) assays
All reactions were performed in 300 pi volumes and the following were common
to each reaction: 2.25 mM ATP, 15 mM MgCh, 150 mM hydroxylamine and 50 mM
HEPES pH 7.4. To assess which enzyme utilized citrate as a substrate, 5 pM SbnC, SbnE
or SbnF were incubated with 3 mM citrate and the common reaction components as
described above. Similarly, to assess which enzyme utilized a-KG as a substrate, 5 pM
SbnC, SbnE or SbnF were incubated with 3 mM a-KG and the common reaction
components. To assess the potential recognition of citryl-Dae as a substrate by SbnF or
SbnC, this intermediate was formed in overnight reactions containing 2.25 mM ATP,
15 mM MgCl2 , 3 mM sodium citrate, 50 mM Dae, 5 pM SbnE buffered in 50 mM
HEPES pH 7.4. This reaction was then heat treated at 70°C to deactivate SbnE and the
reaction was then centrifuged at 20 000 g for 10 min to pellet precipitated enzyme. The
supernatant which now contains the citryl-Dae intermediate was incubated with fresh
5 pM SbnF or SbnC, 2.25 mM ATP and 150 mM hydroxylamine. To assess the potential
recognition of citryl-Dap as a substrate for SbnF or SbnC, this intermediate was formed
as described above except that Dae was replaced with 50 mM Dap instead. For each
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reaction, a duplicate control reaction was prepared in which the enzyme was previously
inactivated by heating at 100°C for 10 min. All reactions described above were incubated
at room temperature in the dark for 1 h before addition of 300 pi of stopping solution
which consisted of 10% (w/v) FeCh and 3.3% (w/v) trichloroacetic acid in 0.7 M HC1.
Reactions were centrifuged at 20 000 g for 5 min to remove precipitate and the formation
of ferric hydroxamate was detected spectrophotometrically at 540 nm. Relative
absorbance values reported in this study were calculated by subtracting the absorbance of
the control reactions (boiled enzyme) from the absorbance of experimental reactions.
2.2.10. Determination of SbnE kinetics
Determination of extinction coefficient for citryl-hydroxamate. A series of
enzyme reactions containing different concentrations of sodium citrate ranging from
100 pM to 30 mM were incubated overnight with 2.25 mM ATP, 15 mM MgCl2 ,
150 mM hydroxylamine, 50 mM HEPES pH 7.4 and 5 pM SbnE. After addition of
stopping solution and measurement of absorbance at 540 nm, a linear relationship
between absorbance and concentration of sodium citrate was established. The extinction
coefficient of the citryl-hydroxamate was determined to be 0.45 m M 1cm '. This
extinction coefficient is similar to that which was obtained for the citrate-specific AcsD
enzyme (achromobactin biosynthesis) from P. syringae pv. syringae B728a (21).
Determination of Km, Vmax and Kcat. To determine the kinetic parameters of
SbnE catalysis, 500 pM citrate was incubated with 2.25 mM ATP, 15 mM MgCl2 ,
150 mM hydroxylamine, 50 mM HEPES pH 7.4 and 3 pM SbnE. The resulting product
conversion rate remained linear up to 10 min and gave an approximately 14% substrateto-product conversion. Therefore, reaction rates were measured spectrophotometrically at
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the 10 min time point with citrate concentrations ranging from 0.25 to 30 mM. Reaction
rate values at each citrate concentration were fitted to the Michaelis-Menten equation and
analysed by non-linear regression. Due to the limit of detection and instability of the
hydroxamate product formed by SbnC, we were unable to evaluate the kinetic parameters
for this enzyme. This phenomenon has been previously observed (21).
2.2.11. Staphyloferrin B Purification
Using recombinant SbnC, SbnE, SbnF, and SbnH, staphyloferrin B biosynthesis
reactions were set up as described above with the exception of preincubating SbnH with a
5-fold molar excess of pyridoxal phosphate followed by a 3x wash of excess cofactor
from the enzyme using an Amicon® Ultra-0.5 10k filter column (Millipore Corp.)
spinning at 14,000 x g for 5 min. Enzymes, substrates, and remaining cofactors were
incubated for 16 h. The staphyloferrin B reaction mixture was centrifuged in an Amicon®
Ultra-0.5 10k filter column (Millipore) at 14,000 x g for 15 min to remove enzymes. The
filtrate was then supplemented with 3 mM FeCh and centrifuged at 18,000 x g to remove
any precipitate. Fifty pi of the solution was then injected onto a Waters xTerra C l8
reversed-phase 5-pm column (150 x 2.1 mm) fitted onto a Beckman System Gold HPLC
equipped with a photodiode array detector. Samples were run at 0.2 ml/min using a step
gradient as described previously (12). Solvent A was 10 mm tetrabutylammonium
phosphate, pH 7.3, in HPLC grade water (Fisher), and solvent B was 100% acetonitrile
(Fisher), and peaks were monitored at 340 nm. The peak corresponding to FeSB eluted at
4—6 min and was collected. Collected fractions were then vacuum-centrifuged until dry
and resuspended in deionized water. The siderophore resuspension was then analyzed by
Q-TOF mass spectrometry as described above to confirm the presence of SB. The
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presence of EDTA in samples analyzed by Q-TOF allowed the detection of iron-free
staphyloferrin B but not the iron-loaded form. Samples run in the absence of EDTA
allowed detection of a mixture of the iron-free and iron-loaded forms of the siderophore.

Other Siderophores
Staphyloferrin A was synthesized and purified as described previously (22), and
desferrioxamine B (used as Desferal™) was purchased from the London Health Sciences
Centre (London, Canada).

2.2.12. Determination of Ferric Staphyloferrin B Concentration
Atomic absorption spectrometry was used to determine the concentration of iron
in HPLC-purified FeSB samples. Therefore, the concentration of iron was used to
determine the concentration of staphyloferrin B after assuming a 1:1 molar ratio of iron to
siderophore in an FeSB complex. Samples were diluted in 1 M nitric acid before being
drawn by an SPS five-sample preparation system (autosampler) into a Varian AA240
atomic absorption spectrometer. Absorbance was detected by an iron/manganese hallow
cathode lamp, which emits at 248.3 nm specific for iron detection. Absorbance data were
analyzed and compared with a linear calibration curve based on known iron standards in
ppm. Iron standards were diluted in 1 M nitric acid from an atomic absorption
spectrometer certified 1000 ppm ± 1% stock (Fisher). Calibration standards were
separately analyzed first before FeSB samples.
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2.2.13. Fluorescence Spectroscopy
Fluorescence titration experiments were performed at room temperature using
recombinant SirA (15 nM) buffered in 50 mM HEPES, pH 7.4, with a Fluorolog-3
spectrofluorometer (ISA Instruments). The excitation and emission slits were set at 2.1
and 6.3 nm, respectively. The excitation and emission wavelengths were set at 280 and
340 nm, respectively, in order to measure the quenching of intrinsic tryprophan
fluorescence of the SirA protein. Dissociation constants (K<j) and relevant parameters
were calculated by fitting the fluorescence titration data for FeSB (across a concentration
range between 0.1 and 112 nM ligand) to a one-site binding model accounting for ligand
depletion. Data were analyzed by nonlinear regression analysis as described previously
(15,23).

2.2.14. Computer analyses
DNA sequence analysis and polymerase chain reaction oligonucleotide primer
design were performed using Vector NTI Suite (Informax) and MacVector software
packages. Graphpad Prism was used for data analysis and graphing applications.
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2.3. Results
2.3.1. The S. aureus sbn operon is associated with production of staphyloferrin B
Staphylococcus aureus strains Newman and RN6390 produce the siderophore SA
under iron starvation growth conditions (11), and the genetic determinants (a four-gene
locus, sfaA-D) for SA biosynthesis in S. aureus were recently identified and characterized
(11,12). Analysis of deletion mutants demonstrated that in strains RN6390 and Newman,
siderophore production was determined by two genetic loci - the aforementioned sfa
locus as well as the previously described, nine-gene shn operon (11,13) (Figure 2.1A).
Given that mutations in the orthologous gene cluster in Ralstonia solanacearum and
R. metaUodurans result in the loss of SB (14) (Figure 2.IB), it was reasonable to
hypothesize that products of the shn operon in S. aureus synthesize SB. Therefore, ironstarved spent culture supernatant from S. aureus H I661 (RN6390 Asfa) (note: a SAdeficient genetic background was used to simplify siderophore extraction and analysis)
was analysed for the presence of SB, and compared with that of S. aureus H I649
(RN6390 AsfaAsbn). As illustrated in Figure 2.2, SB ([M-H]' = 447.14) was detected in
the iron-starved spent culture supernatant of H I661, but not H I649, confirming that the
sbn operon is involved in the synthesis of this siderophore. Previous results demonstrated
that culture supernatants of HI 661, but not HI 649, could promote the iron-starved growth
of S. aureus, as would be expected should H I661 synthesize a molecule with siderophore
properties (11).
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Figure 2.1. The S. aureus sir-sbn genetic locus and chemical structure of
staphyloferrin B. (A) Physical map of the S. aureus sir-sbn genetic locus. Predicted
products highlighted are type A (angle lines), type B (solid) and type C (vertical lines)
NIS synthetases and a decarboxylase (dotted). (B) Structure of staphyloferrin B.
Components of the siderophore are indicated.
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Figure 2.2. Identification of staphyloferrin B production by S. aureus RN6390. Top
panel: Concentrated spent culture supernatant from iron-starved S. aureus RN6390 sfa
was subjected to LC-ESI-MS analysis. Shown is the selected ion chromatogram for the
ion at m/z 447.1 from LC-ESI-MS and the ESI-MS spectra (inset) of the region in the
chromatogram indicated by the horizontal black bar. Bottom panel: Same as the top panel
but material was obtained from an iron-starved S. aureus RN6390 AsfaAsbn mutant.
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2.3.2. In vitro synthesis of staphyloferrin B requires three NIS synthetases (SbnCEF)
and a decarboxylase (SbnH)
Bioinformatic analyses of the predicted protein products from the SB biosynthesis
operon identified three enzymes (SbnC, SbnE and SbnF) that belong to the NIS family of
siderophore synthetase enzymes. From previous studies, it is known that these enzymes
catalyse the ATP- and Mg24-dependent activation of carboxylate substrates, in a reaction
that proceeds through an acyl-adenlyate intermediate that is then condensed with an
amine substrate which would generate an amide product (12,21,24-26). To examine the
activity of the SbnC, SbnE and SbnF enzymes, and to determine if they were sufficient
for SB synthesis, each was independently overexpressed in E. coli as a hexahistidinetagged derivative, and subsequently purified using nickel-affinity chromatography
(Figure 2.3A). When the three synthetases were incubated together with SB components
Dap, citrate, Dae and a-KG, an ion corresponding to SB was not formed (Figure 2.3B,
top panel). Given the possibility that an additional Sbn enzyme was a required component
in the SB biosynthetic pathway, additional purified Sbn enzymes were added to the
reaction. Notably, when SbnH, a putative pyridoxal-5'-phosphate (PLP)-dependent
decarboxylase, was combined in reactions with the three synthetases and substrates, an
ion corresponding to that of SB was produced (Figure 2.3B, bottom panel). The SB ion
was not produced when any of ATP, Mg2+, SbnC, SbnE, SbnF, SbnH, Dap, citrate or aKG was omitted from the reaction (data not shown). Notably, SB synthesis could proceed
even without the addition of Dae in the reaction (see below for further discussion). ESIMS/MS was used to confirm that SB produced in vitro was the same as that isolated from
spent

culture

supernatants

of

iron-starved

S. aureus

(Figure

2.4).
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Figure 2.3. Analysis of the in vitro synthesis of staphyloferrin B (SB). A) SDSpolyacrylamide gel showing the purification of SbnC, SbnE, SbnF and SbnH proteins. B)
Selected ion chromatograms for the ion at m/z 447.1 and ESI-MS mass spectra (inset) of
the region in the chromatogram shown by the black horizontal bar. Also included in the
spectra are species corresponding to ATP and ADP (ATP is included in reactions at a
concentration of 5 mM), which serve the purpose of internal standards. Enzyme reactions
contained citrate, 1-2,3-Dap, a-KG, ATP, Mg2+, SbnC, SbnE, SbnF without (top panel) or
with (bottom panel) inclusion of SbnH. The mass ion at m/z 447.1 is staphyloferrin B [M
H]", and this mass ion was not observed when any of the above-mentioned reaction
components were omitted.
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Figure 2.4. ESI-MS/MS fragmentation pattern of ions at m/z 447.1 (staphyloferrin B) is
identical between samples obtained in vz'vo[i.e. from material obtained from culture
supernatants (Figure 2.2, top panel)] and in vitro[i.e. from material synthesized in vitro
(Figure 2.3B, bottom panel)]. The [M-H]“ ion fragments to give daughter ions resulting
from losses of water and carbon dioxide, as indicated.
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2.3.3. In vitro synthesized staphyloferrin B is biologically active
Having established that SB can be produced in vitro, it was important to show that
the molecule had the same biological properties (i.e. the ability to deliver iron to bacteria)
as that of SB produced by S. aureus cells. This was confirmed by showing that enzymatic
reaction material derived from complete reactions (i.e. those containing citric acid, Dap,
a-KG, ATP, Mg2+ and SbnCEFH; see Figure 2.3), and not that derived from reactions
lacking any one component (e.g. lacking ATP or one or more enzymes), could readily
promote the iron-starved growth of siderophore-deficient S. aureus (i.e. AsfaAsbn) in a
concentration-dependent fashion (Figure 2.5A). This SB-dependent growth promotion
was mediated by the ABC transporter SirABC (Figure 2.5B), which is encoded by the
sirABC operon divergently transcribed from the sbn operon (Figure 2.1A).

2.3.4. SbnE, a citrate-desymmetrizing enzyme, initiates staphyloferrin B synthesis
Staphylococcus aureus SbnE is 578 amino acid protein with a calculated molecular mass
of 66 kDa and an estimated isoelectric point (pi) of 5.52. Bioinformatic analyses place the
enzyme in the IucA/IucC family of NIS synthetases and, more specifically, into the type
A subfamily (4). Blast searches demonstrate that SbnE shares significant similarity with
the type A enzymes AsbA (initiates petrobactin synthesis in Bacillus anthracis) (27) and
AcsD

(initiates

achromobactin

synthesis

in Pectobacterium chrysanthemi and

Pseudomonas syringae) (6,21). The type A enzymes are specific for condensation
reactions involving citric acid and more importantly, a recent thorough study on AcsD
from P. chrysanthemi showed that this enzyme catalysed the stereospecific adenylation of
one of the prochiral carboxymethyl groups of citrate, which primes it for reaction with
nucleophilic L-serine to form an achromobactin precursor (6).
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Figure 2.5. In vitro synthesized staphyloferrin B (SB) is biologically active. A)
Increasing amounts of SB from complete reactions promoted increasing growth of ironstarved S. aureusAsfaAsbn, reaching levels comparable to those obtained when 50 pM
FeCl3 was added to culture media. Material from reactions that lacked either ATP or Sbn
enzymes failed to promote growth. B) An intact SirABC transport system (see Figure
2.1 A for physical map of sir-sbn locus) is required for SB-dependent iron acquisition
observed either in liquid growth media or in siderophore plate bioassays (inset). As
described in Experimental procedures, the SB biosynthesis reactions produced 1 nM
Desferal™ equivalents of SB as determined using the CAS siderophore detection assay.
Each data point represents the mean ± SD of triplicate samples.
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To assay for enzymatic activity of SbnE, the hydroxylamine trapping assay
(described in Kadi and Challis, 2009) was used. Essentially, this assay is used to monitor
the specific activity of a synthetase towards a particular carboxylic acid. As illustrated in
Figure 2.6, of the three NIS synthetases tested (SbnC, SbnE and SbnF), only SbnE
showed a high level of specific activity towards citrate as a substrate. In the structure of
SB (Figure 2.IB), citrate is joined on either side by Dap and Dae. Liquid
chromatography-electrospray ionization-mass spectrometry (LC-ESI-MS) was used to
demonstrate that upon incubation with citrate and Dap, SbnE readily catalysed the ATPdependent formation of a mass ion species of [M-H]' at m/z 277.1 (Figure 2.7A),
consistent with the formation of [3] (Figure 2.8). This reaction product reacted strongly
with CAS reagent but was unable to promote the iron-starved growth of S. aureus (data
not shown). The SbnE-dependent condensation of citrate with Dap was further confirmed
by the appearance of a mass ion at m/z 279.1 when citrate-2,4-13C2 replaced citric acid in
the reaction (Figure 2.7A). SbnF, which showed some activity towards citrate in
hydroxylamine assays (Figure 2.6), was unable to form the citryl-Dap intermediate
(Figure 2.7A).
The kinetics of the recognition of citrate by SbnE were determined using the
hydroxylamine trapping assay, and were as follows: Km = 0.99 mM ± 0.12 and
ATCat = 16.08 min”1± 0.87. Michaelis-Menten kinetics were observed at substrate
concentrations as high as 30 mM citrate. It was of interest to determine if SbnE could also
carry out a condensation reaction between citrate and Dae. The bottom three panels of
Figure 2.7B and Figure SI (see Appendix) illustrate that this reaction does occur, but
that when presented with equimolar concentrations of citrate, Dap and Dae, SbnE readily
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forms the citryl-Dap intermediate ([M-H]" at m/z 277.1) and virtually no mass ion species
that would correlate with the formation of citryl-Dae ([M-H]' at m/z 233.1). Therefore,
this suggests that Dap is the preferred amine substrate for SbnE.

2.3.5. SbnH carries out PLP-dependent decarboxylation of the citryl-Dap
intermediate
SbnH is 400 amino acids in length and has a mass of 45.8 kDa and an estimated pi
of 5.85. SbnH shares significant sequence similarity with PLP-dependent decarboxylase
enzymes, among them AscE from the achromobactin biosynthetic gene cluster. SbnH
overexpressed and purified from the cytoplasm of E. coli had an intense yellow colour
which suggests a population of the enzyme exists in the PLP-bound form. As described
above, our data demonstrated the sine qua non role of SbnH in SB synthesis. It was of
interest therefore to define at which step the decarboxylation occurs in the pathway. As
illustrated in Figure 2.3, SB biosynthesis was dependent on the presence of substrates
citric acid, Dap and a-KG, but not Dae, in the presence of SbnCEFH. This is noteworthy
because theoretical decarboxylation of Dap would produce Dae. However, SbnHdependent decarboxylation of Dap to yield free Dae as a substrate is unlikely to be a
biologically relevant process since, as shown in Figure 2.7B and Figure SI, free Dae is
only poorly incorporated onto citrate by SbnE, and especially in the presence of Dap.
Therefore, this would indicate that decarboxylation occurs preferentially on an SB
intermediate. As demonstrated in Figure 2.7B and Figure SI, when SbnH was added to
reactions containing SbnE, citric acid and Dap, an [M-H]' ion at m/z 233.1 appeared, in
agreement with a proposed decarboxylation reaction on [3] to yield [4], In reactions
where citric acid-2,4-13C2 replaced citric acid, the mass ion of [M-H]' at m/z 233.1
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disappeared and was shifted up two mass units. The appearance of an SB-intermediate
species at [M-H]' at m/z 235.1 was not obvious in reactions buffered with HEPES since it
has the same mass as that of the deprotonated form of HEPES buffer (two predominant
mass ions are observed for HEPES, one at 237.1 and another at 235.1) (Figure 2.7B). To
circumvent this problem, the reactions were also performed in phosphate buffer, pH 7.4.
Using phosphate buffer, the 233.1 to 235.1 mass ion shift due to replacement of citrate
with citrate-2,4-13C2 in the reactions is readily apparent given the absence of interfering
background in this region of the spectra (Figure SI).

2.3.6. SbnF is necessary to form a staphyloferrin B intermediate

SbnF is a 592-amino-acid protein with a theoretical mass of 68.9 kDa and an
estimated pi of 5.07. Bioinformatic analyses, along with the known structure of SB,
indicate that SbnF, a putative type C synthetase, generates an amide bond between an
amino- or hydroxyl-containing substrate and a second substrate which is already a
monoamide but still possesses a free prochiral carboxyl. Thus, given that our data were
consistent with the generation of [4] from a reaction containing SbnE, SbnH, citrate and
Dap, we postulated that SbnF could act on this intermediate to add a molecule of Dap,
which would be consistent with the known structure of SB (see Figure 2.1). The potential
substrate was first examined using substrate trapping (hydroxylamine) assays. Not
surprisingly, SbnF did not react with the citryl-Dap product of a reaction containing
SbnE, citrate and Dap (the mass ion at m/z 277.1 corresponding to [3]) (Figure 2.6). To
determine whether SbnF recognizes a citryl-Dae intermediate as a substrate in the
hydroxylamine assays, we attempted to use the product of reactions containing SbnE,
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SbnH, citrate and Dap (which yields a mass ion of 233.1 consistent with citryl-Dae [4]).
Unfortunately, it was determined that PLP, which is associated with SbnH, interfered
with the assay. To overcome this, citryl-Dae was generated by reacting SbnE with citrate
in the presence of a 17-fold molar excess Dae compared with substrate concentrations
that were used for routine reactions set up for all LC-ESI-MS experiments. In this case,
SbnF showed high levels of activity with the citryl-Dae intermediate (Figure 2.6). In the
structure of SB, the Dae molecule is linked to citrate and Dap. Therefore, it was
reasonable to assume that SbnF recognized and condensed the citryl-Dae intermediate
with Dap. This reaction would generate a species of [M-H]' at m/z 319.1. LC-MS
confirmed that this species appeared in ATP-dependent reactions containing SbnE, SbnH,
SbnF, citrate and Dap (Figure 2.7C). Mass ions of 233.1 and 277.1 were also detectable
in these reactions. When reactions contained citrate-2,4-13C2 in place of citrate, the m/z
233.1, 277.1 and 319.1 mass ions were each shifted two mass units higher (Figure 2.7C).
Consistent with the hydroxylamine assay results showing that SbnF did not react with the
SbnE-catalysed citryl-Dap product, we could not detect a mass ion of m/z 363.1 (Dapcitryl-Dap) when SbnF was reacted with SbnE, citrate and Dap (data not shown). All
together, the data are consistent with SbnF acting in the pathway subsequent to SbnE and
SbnH, and generating [5] by condensing one molecule of Dap with [4],

2.3.7. SbnC activates a-KG in a reaction that completes the synthesis of
staphyloferrin B
SbnC is a 584 amino acid protein with a mass of 66.4 kDa and an estimated pi of
4.93. SbnC groups with type B synthetases based on bioinformatic analyses (4), meaning
that it putatively catalyses amide bond formation between an amino or hydroxyl group of
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one substrate and the C5 carboxyl group of a-KG. In agreement with this prediction, the
hydroxylamine-trapping assay showed that SbnC, but not SbnE or SbnF, activates a-KG
(Figure 2.6). As described above (illustrated in Figure 2.3), LC-ESI-MS demonstrated
that reactions containing a-KG, citrate, Dap, SbnE, SbnH and SbnF (i.e. lacking SbnC) do
not form SB (no mass ions of 447.1 in negative ion mode detectable above background)
but do form a mass ion of m/z 319.1 that correlates with compound [5] (data not shown).
As shown in Figure 2.3 and again in Figure 2.7D (top spectrum), complete reactions (i.e.
all four enzymes and three SB component substrates) readily synthesized a mass ion at
m/z 447.1, consistent with the mass of SB. The mass of SB was two mass units heavier
when citrate was replaced with citrate-2,4- l3C2 (Figure 2.7D, second spectrum). The ATP
dependence of the synthesis was again confirmed in the third spectrum shown in Figure
2.7D, as was the requirement for SbnH, even in the presence of Dae (Figure 2.7D, fourth
spectrum). In the latter case, a build-up of the mass ion at m/z 277.1 was readily observed,
in agreement with blockade of the pathway after the first enzymatic step (Figure 2.8).
Taken together, these data are consistent with the hypothesis that SbnC condenses a-KG
with [5] in the final step of SB biosynthesis.
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Figure 2.6. Substrate specificity determination for Sbn enzymes. Sbn enzymes were
mixed with carboxylic acid substrates in reactions that contained ATP, Mg2+ and
hydroxylamine. Assays, performed according to published procedures (26), detected the
production of hydroxamates. Results are presented for reactions using the carboxylic acid
substrates citrate, cityrl-Dap, citryl-Dae and a-KG. Citryl-Dap and citryl-Dae were
prepared from reactions that contained ATP, Mg2+, SbnE, citrate and either Dap or Dae
respectively.
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Citrate

Citryl-Dap
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Figure 2.7. LC-ESI-MS data to identify mass ions consistent with proposed
staphyloferrin B biosynthetic intermediates. In each panel, MS spectra focused on
mass ranges for identification of particular intermediates for the first (A), second (B),
third (C) and final (D) steps in SB biosynthetic pathway, as outlined in Figure 2.8. Each
data set resulted from reactions run in HEPES buffer (see Experimental procedures) and
was normalized to the intensity of a particular mass ion present in the samples (e.g.
HEPES or ADP).
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Figure 2.8. Proposed scheme for the biosynthesis of staphyloferrin B. Abbreviations
used: aKG, a-ketoglutarate; PLP, pyridoxal-5'-phosphate.

107

OH

/
L-2,3-diaminopropionic acid [1]

citric acid [2]

citryl-L-2,3-diaminopropionic acid [3]

citryl-diaminoethane [4]

[M-H]-= 103.06

[M-H]' = 191.03

[M-H]- = 277.08

[M-H]’ = 233.09

ATP

AMP,
PPi
L-2,3-diaminopropionyl-citryldiaminoethane [5]

staphyloferrin B

[M -H ]'= 319.13

[M-H]- = 447.14

108

2.3.8. S. aureus imports ferric-staphyloferrin B via the SirABC transporter
Thus far we have shown that staphyloferrin B can be synthesized by enzymes
encoded by the sbn operon in S. aureus and is transported through the SirABC transport
system. This was demonstrated using complete SB reaction mixtures that were able to
promote growth of S. aureus AhtsABC mutants but not sirA mutants, as demonstrated
using siderophore plate bioassays (see Figure 2.5B). It is worthy to note that equivalent
bioassay results were obtained using HPLC purified FeSB (fractions collected at the 4—6
min window of the HPLC chromatogram, Figure 2.9A). No other HPLC fractions
promoted growth of S. aureus (data not shown). Q-TOF mass spectrometry on the
bioactive fractions confirmed the presence of SB with mass ion [M-H]~ = 447.1 (Figure
2.9B). In contrast, reaction mixtures containing no enzymes or ATP did not produce the
FeSB peak on HPLC; nor did they promote the growth of S. aureus (data not shown). The
observation that FeSB was only able to promote the growth of S. aureus AhtsABC and not
strains harboring a sirA mutation highlights the specificity and requirement of the SirABC
transport system for the recognition and import of the FeSB complex.

2.3.9. Ferric-staphyloferrin B and SirA binding
SirA is a class III substrate binding protein that is N-terminally lipidated and
serves as the receptor for ferric staphyloferrin B. Fluorescence spectroscopy (with respect
to intrinsic tryptophan fluorescence) was used to measure the affinity of this receptor
protein (overexpressed and purified without the lipidation signal) for its siderophore
ligand. Titrations of HPLC-purified FeSB with recombinant SirA revealed a dissociation
constant (KJ) that is in the low nanomolar range (Figure 2.10). Due to a limitation in the
fluorescence intensity, we are unable to report an accurate Kj value other than an upper
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limit (low nanomolar). The affinity observed for SirA and SB resembles the affinity
observed for HtsA and SA (28). The specificity of SirA for FeSB was further
demonstrated by using FeSA (another a-hydroxycarboxylate siderophore) and Fedesferrioxamine (an unrelated hydroxamate siderophore). Using either of the latter ironsiderophore complexes, some fluorescence quenching was observed but never reached the
level of quenching observed for the FeSB complex (Figure 2.10), suggestive of
nonspecific quenching or photobleaching of the protein.
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Figure 2.9. Synthesis and purification of in vitro synthesized staphyloferrin B. A)
HPLC traces of in vitro SB synthesis, demonstrating that enzymes and ATP are required
for SB synthesis. B) Q-TOF mass spectrometry identified the main constituent of in vitro
purification as having a mass ion [M-H]~ = 447.1 as expected for SB. mAu,
milliabsorbance units.
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Figure 2.10. Fluorescence quenching of SirA upon ligand binding. Fe(III)-loaded
staphyloferrin B, staphyloferrin A, and desferrioxamine were titrated into SirA, and
quenching of fluorescence was monitored. Titrations were preformed with concentrations
of Fe(III)-siderophores between 0 and 120 nM, but only data from 0-30 nM are shown.

Relative Fluorescence Intensity
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2.4. Discussion
Iron, or, more appropriately, its availability, plays a central role in the hostpathogen relationship. Whereas the host has developed numerous strategies to thwart
pathogens by sequestering this essential nutrient, many pathogens have countered by
evolving specialized iron acquisition mechanisms. S. aureus is a significant human and
animal pathogen which has the capability to scavenge haem, doing so by releasing
extracellular toxins that lyse erythrocytes, resulting in the release of haemoglobin. A
specialized series of proteins (iron-regulated surface determinants) is expressed on the
surface of S. aureus, of which the cumulative function is to affect the cell surface binding
of haemoglobin and the subsequent release and transport of haem into the cell for its use
in biological processes (29-32). S. aureus is an interesting pathogen because not only
does it acquire iron from haem, but it also produces at least two siderophores, of which
the structures of SA and SB are known.
In this study, we describe the first characterization of the biosynthesis of SB, and
demonstrate cell-free synthesis of SB. SB is composed of Dap, citric acid, Dae and a-KG.
Given that the structure of the siderophore contains carboxylic acids and amines, it was
not surprising that it would be synthesized in an NIS-dependent manner, and would likely
require the activity of three NIS synthetases. The sbn gene cluster, which encodes three
NIS synthetases (SbnCEF), was previously associated with the production of a
siderophore that was not structurally elucidated (13). As described here, we took
advantage of S. aureus deletion mutants to show that strains deleted for sfa (i.e. do not
synthesize SA) make readily detectable amounts of SB. SB synthesis in S. aureus was
dependent on the sbn genes since the siderophore was not detected in culture supernatants
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of a mutant containing deletions of both the sfa and sbn gene clusters.
In order to elucidate the SB biosynthetic pathway, Sbn proteins were purified and
reacted with SB components. It is noteworthy that inclusion of the three synthetases
(SbnCEF) along with ATP, Mg2+ and the four component substrates of SB, in a one-pot
assay, did not result in the formation of SB. SB was only formed with the inclusion in the
assay of the PLP-dependent decarboxylase, SbnH. Moreover, with SbnH included in
reactions, Dae as a component substrate was not required for SB synthesis to proceed.
This would suggest that the essential decarboxylation step occurs on a Dap-containing
intermediate (decarboxylation of Dap yields Dae) and argues against SbnH activity on the
Dap substrate before its inclusion into the growing structure. The data are consistent with
decarboxylation of [3] to yield [4] (Figure 2.8). Although the data demonstrated that a
decarboxylation step was required for SB synthesis (specifically for decarboxylation of
the SbnE-derived citryl-Dap intermediate to a citryl-Dae intermediate), we could still
show that SbnE was capable of directly condensing Dae with citrate, presumably
bypassing the requirement for a decarboxylation step. This would be similar to data
recently published on the achromobactin biosynthetic pathway (21). In the biosynthesis
of achromobactin, which

is comprised of citrate,

a-KG,

ethanolamine and

diaminobutyrate, the first step is the AcsD (analogous to SbnE)-dependent condensation
of citric acid with serine, and this intermediate is thought to be decarboxylated to Ocitryl-ethanolamine. Berti and Thomas (2009) have shown that if AcsD were instead
provided with citric acid and ethanolamine, the O-citryl-ethanolamine intermediate could
be formed, thus bypassing a predicted PLP-dependent AcsE (analogous to SbnH)mediated decarboxylation step and allowing synthesis of the complete achromobactin
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siderophore structure. In contrast, in the SB pathway, we have shown that a
decarboxylation step is required for SB synthesis and, presumably, as a result of our data
indicating that SbnE strongly favours condensation of citrate with Dap as opposed to Dae
(Figure 2.7D). Since another molecule of Dap is required to form the final structure, it is
impossible to bypass the requirement for Dap in the synthesis of SB. Moreover, the in
vivo concentration of Dap is likely to be higher than that of Dae, especially since we have
evidence that the SbnA and SbnB enzymes synthesize Dap (F.C. Beasley, J. Cheung and
D.E. Heinrichs, unpubl. obs.) as a method to ensure the presence of this precursor.
An important difference between the achromobactin and SB pathways is the lack
of processive addition of a-KG to the structure of SB by a type B enzyme (SbnC for SB
and AcsA for achromobactin). It has been observed that two successive a-KG molecules
are condensed onto the achromobactin intermediate by AcsA to form the final
siderophore, provided that the serine in the a-ketoglutaryl-diaminobutryl-citryl-serine
intermediate has been decarboxylated prior to addition of the second a-KG (21). It is
possible in this case that the carboxyl group on serine acts as a steric obstacle preventing
AcsA from adding another a-KG to the intermediate. By comparing this observation with
the known structure of SB (Figure 2.8) we can make the analogy that the presence of the
carboxyl group on Dap is similarly inhibiting SbnC from processively adding a second aKG to the SB structure. This is yet another interesting difference in SB because we have
shown in this study that the decarboxylation event by SbnH occurs on [3] in order for
SbnF to recognize it as a substrate (Figure 2.7B and C). Even when all four enzymes
were incubated with citrate, Dap, a-KG, Mg2+ and ATP, we were unable to observe a
mass ion that corresponded to a mass of SB, decarboxylated and condensed with another
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molecule of a-KG ([M-H]' at m/z 531) by LC-ESI-MS (data not shown). Therefore, SbnH
is unable to decarboxylate the Dap on either [5] or the full SB structure to generate
another Dae moiety that might serve as an adequate nucleophile for a condensation with a
second a-KG.
Challis (2005) used bioinformatics to propose that NIS synthetases fall into three
basic types (A, B and C), grouped according to specificity for particular carboxylic acids.
In this study, we have demonstrated that SbnE has type A NIS activity, SbnC has type B
NIS activity and SbnF has type C NIS activity, as predicted by the phylogenetic analyses,
thus demonstrating the general robustness of the bioinformatic-based predictions. To
date, of the close to 100 NIS synthetase enzymes identified through genome mining, only
a few have been biochemically characterized (6,25-27). The SB pathway is interesting to
study because it uses a representative of each of the three synthetase types, thus
representing a good model system to study. Cotton et al. have recently shown that the
two type A NIS synthetases in the SA pathway cluster with the type B NIS synthetases,
thus forming a new subtype of enzymes with A-type chemistry (12) and highlighting the
need for continued biochemical studies of these important enzymes to elucidate their
activity.
In a recent landmark study, Schmelz et al. (2009) defined a high-resolution crystal
structure of the type A NIS enzyme AcsD from P. chrysanthemi. They provided
important insight into the mechanism of action of this family of proteins by observing the
acyladenylate intermediate that is formed during activation of one of the prochiral
carboxylate groups of citrate. Subsequent attack by an amine nucleophile (L-serine in the
case of AcsD) results in a condensation reaction and release of the citryl-L-serine
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siderophore intermediate. This points out a key difference between NIS and NRPS
systems. In the latter, intermediate structures remain associated with the modular
synthetic machinery. In the case of the former, one might suspect that protein:protein (i.e.
synthetase:synthetase) interactions may be involved that would ensure greater efficiency
in the synthesis of the siderophore molecule, in light of the fact that intermediate
structures are freely dissociable from the NIS synthetases. The possible existence of
higher-order protein complexes for these biosynthetic pathways remains to be
determined.
This study adds to the recent and rapid progress in our understanding of the
function of NIS synthetases, an important class of bacterial enzymes. We demonstrate,
for the first time, the in vitro synthesis of biologically active SB by combining three
synthetases and a decarboxylase in one-pot enzyme reactions, and propose a biosynthetic
pathway. This is an important step towards more detailed mechanistic and structural
studies on the synthetases and their reaction products.
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Chapter 3:
Identification and characterization of a novel, iron- regulated citrate synthase in
Staphylococcus aureus
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3.1 Introduction
Staphylococcus aureus is a notorious Gram-positive pathogen capable of
inflicting various types of maladies ranging from boils and impetigo to serious conditions
such as endocarditis and meningitis. Not unlike many other microorganisms, it frequently
faces the challenge of acquiring sufficient amounts of iron for survival. This is because
iron exists in the form of ferric (Fe3+) hydroxide or oxyhydroxide precipitates following
reaction with oxygen (1-3), and thus drastically decreasing the concentration of soluble,
or bioavailable, iron.

To overcome this nutritional obstacle, bacteria have evolved

efficient iron-uptake strategies and the use of siderophores is one of the most common.
Siderophores are low-molecular-weight, high-affinity iron-chelators made of amino acids
and/or non-proteogenic amino acids that are classified depending on the functional
groups used in iron-coordination (4). There are two known methods for synthesis of
siderophores in bacteria. One method invokes the use of non-ribosomal peptide
synthetases (NRJPS) which form large modular enzymatic platforms that synthesize
protein carrier-linked siderophore intermediates (for a review, see (5)). A second strategy
for siderophore synthesis is dubbed the NRPS-independent siderophore (NIS) synthetase
system which strictly utilizes enzymatic condensation of dicarboxylic acids with
diamines and/or amine-alcohols and unlike the NRJPS system, the NIS method involves
freely dissociable enzymes and biosynthetic intermediates (for a review, see (6)). The
model NRPS and NIS-synthesized siderophores are enterobactin and aerobactin,
respectively.
S. aureus produces two a-hydroxycarboxylate siderophores termed staphyloferrin
A and staphyloferrin B (7-10). Staphyloferrin A is comprised of two citrate molecules
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amide linked to a central D-omithine residue, and the sfa gene cluster encodes enzymes
necessary for NIS-type synthesis of the staphyloferrin A molecule (11,12). The
constituent components of staphyloferrin B are L-2,3-diaminopropionic acid (Dap),
citrate, 1,2-diaminoethane, and a-ketoglutarate (7), and the nine-gene sbn operon in S.
aureus encodes the requisite enzymes for synthesis of the staphyloferrin B molecule (2).
The NIS-type biosynthetic pathway for staphyloferrin B has recently been elucidated, and
involves three synthetase enzymes (SbnC, SbnE, and SbnF) and a decarboxylase (SbnH),
and requires the precursors citrate, Dap, and a-ketoglutarate; the 1,2-diaminoethane
component of the siderophore is derived from decarboxylation of one molecule of Dap
(2). Another carboxylate class siderophore that has gained recent attention is
achromobactin, a metabolite that is produced by organisms such as Pseudomonas
syringae and Dickeya dadantii (formerly Erwinia chrysanthemi). The achromobactin
biosynthetic pathway utilizes the siderophore synthetases AcsD, AcsA, and AcsC with
substrates a-ketoglutarate, citrate, L-serine, and diaminobutyric acid (13). In studying the
achromobactin synthetic pathway, Schmelz et al. reported the first high-resolution crystal
structure of a NIS-type siderophore synthetase, AcsD (14). That work elucidated the
catalytic mechanism from activation of a prochiral carboxylate group of citrate to
acyladenylate formation and then priming of this intermediate for attack by the amine
nucleophile (L-serine) which ultimately leads to a citryl-L-serine intermediate.
Although genetic, biochemical, and structural studies have shed light on the
central steps of siderophore biosynthesis, many of the siderophore biosynthesis genetic
loci contain genes whose functions are not yet characterized, and some of these gene
products may be important for precursor synthesis. Precursor synthesis encoded from
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within the siderophore biosynthetic operon would ensure optimal production of the final
metabolite, irrespective of the metabolic status of the cell. Indeed, as described above, S.
aureus synthesizes two citrate-containing siderophores under conditions of iron
limitation. Paradoxically, during iron-limiting growth, S. aureus undergoes a metabolic
shift in what has been termed the 'iron-sparing' response, that is, the expression of non
essential iron-containing enzymes is reduced (15). Many of these enzymes, including
citrate synthase, CitZ, are central to the tricarboxylic acid cycle and, thus, under ironlimiting growth, the production of citric acid through central metabolism is presumably
reduced. How, then, is citric acid synthesized during iron-restricted growth in order to
sustain production of the citrate-containing staphyloferrin siderophores? We reasoned
that production of citric acid could be an activity that is encoded from within the
staphyloferrin B biosynthetic cluster, where several gene products have yet to be
characterized.
In this study, we identify and characterize a novel, iron-regulated class II aldolase,
encoded by sbnG from within the staphyloferrin B biosynthetic operon, that catalyzes an
aldol condensation between oxaloacetate and acetyl-CoA to give rise to citric acid. We
demonstrate this through a combination of coenzyme A release assays and LC-ESI-MS
experiments. Homologs of SbnG are found within the biosynthetic gene clusters of other
citrate-containing siderophores, including achromobactin and vibrioferrin. We propose
that SbnG and homologs act effectively as citrate synthases with the purpose of ensuring
citrate is available as a precursor for siderophore biosynthesis.
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3.2 Experimental Procedures

3.2.1. Bacterial strains, plasmids and standard growth conditions
E. coli were grown in Luria-Bertani broth (Difco). For experiments not directly
involved in the analysis of iron uptake, S. aureus were grown in tryptic soy broth (Difco).
Tris-minimal succinate (TMS) medium was prepared as described (16) and used as an
iron-limited minimal medium. To further restrict the level of free iron in TMS, the iron
chelating compounds 2,2'-dipyridyl and ethylene diamine-di(o-hydroxyphenol acetic
acid) (EDDHA) were added as indicated in the text. Where necessary, kanamycin
(30 pg ml“1) was incorporated into media for the growth of E. coli strains. For S. aureus,
kanamycin (50 pg ml“1) and neomycin (50 pg ml“1) were incorporated into growth media
as required. Solid media were obtained by the addition of 1.5% (w/v) Bacto agar (Difco).
All bacterial growth was conducted at 37°C unless otherwise stated. Iron-free water for
preparation of growth media and solutions was obtained by passage through a Milli-Q
water filtration system (Millipore Corp.).

3.2.2. Recombinant DNA methodology
Standard DNA manipulations were performed essentially as described (17).
Restriction endonucleases and DNA-modifying enzymes were purchased from Roche
Diagnostics (Laval, Quebec, Canada), New England Biolabs (Mississauga, Ontario,
Canada), Life Technologies (Burlington, Ontario, Canada) and MBI Fermentas
(Flamborough, Ontario, Canada). Plasmid DNA was purified using QIAprep plasmid
spin columns (QIAgen, Santa Clarita, California) as described by the manufacturer.
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Polymerase chain reactions were performed using Pwol DNA polymerase (Roche
Diagnostics).

3.2.3. SbnG Overexpression and Purification
The full length of the gene encoding SbnG was PCR-amplified from S. aureus
strain

Newman

using

forward

primer

5'-

TTGATAGCTAGCATGATGCAACAACTATCTCTG-3' [Nhe.I) and reverse primer 5'TTGATAGGATCCTTAGCCTTCATCCCCTTTC-3’ (BamHl).

The amplicon was

digested with Nhel and BamHl and cloned into Nhel-BamHl-digested pET28a(+)
(Novagen), which incorporates a thrombin-cleavable His6 tag at the N-terminus of the
encoded recombinant protein. The pET28-SbnG construct was introduced into E. coli
BL21(/X)E3). Cells were grown at 37°C to an optical density of approximately 0.8, at
which time isopropyl P-D-thiogalactoside (IPTG) (0.5 mM) was incorporated into the
growth medium. The cells were then incubated for an additional 16 hours at room
temperature with shaking at 300 rpm and cells were then harvested by centrifugation at
15 000 x g for 15 minutes. The cell pellet was resuspended in 50 mM HEPES pH 7.4,
500 mM NaCl, and 10 mM imidazole and lysed in a French pressure cell at 10 000 psi.
The cell lysate was then centrifuged at 15 000 x g f o r 15 minutes to remove unbroken
cells and debris. The supernatant was then subjected to ultracentrifugation at 150 000 x g
for 60 minutes to remove insolubles. The soluble material was applied to a nickel-loaded
1-mL HisTrap column (GE Healthcare) equilibrated with buffer A (50 mM HEPES
buffer (pH 7.4), 500 mM NaCl, l OmM imidazole) and the His6-tagged protein was
eluted from the column with a gradient of 0-80% buffer B (50 mM HEPES buffer

127

(pH 7.4), 500 mM NaCl, 500 mM imidazole) over 20 column volumes using an AKTA
FPLC (GE Healthcare). Protein fractions were collected and dialysed against phosphate
buffered saline at 4°C in preparation for thrombin protease treatment as per manufacturer
instructions. Thrombin-treated SbnG was then applied onto a nickel-loaded, 1-mL
HisTrap column to separate the His6 tag from SbnG protein. SbnG was collected in the
flowthrough and dialyzed against 20 mM Tris-HCl, pH 7.5, 150 mM NaCl at 4°C. SbnG
was then further purified using anion exchange chromatography by loading the protein
onto a Mono-Q 10/10 column (GE Healthcare) equilibrated with buffer C (20 mM TrisHCl, 150 mM NaCl) and eluting the protein using a 0-100% gradient of buffer D (20 mM
Tris-HCl, 1M NaCl). Fractions containing SbnG were dialyzed at 4°C into storage buffer
consisting of 50 mM HEPES pH 8.0, 150 mM NaCl, 10% glycerol. Protein purity was
confirmed using ESI-MS and SDS-PAGE. Purified SbnG was then aliquotted and stored
at -80°C. Typical SbnG yield from the induced E. coli cultures was determined to be 30
40 mg/L.

3.2.4. Size-exclusion chromatography
Purified SbnG was buffer exchanged to 50 mM HEPES, pH 7.4, 150 mM NaCl
using an Amicon® Ultra-0.5 10K filter column (Millipore Corp.), prior to loading onto a
Superdex-200 10/30 GL analytical gel filtration column (GE Healthcare) equilibrated
with the same buffer. The column was calibrated with blue dextran (void volume; 7.95
mL), P-amylase (200 kDa), alcohol dehydrogenase (150 kDa), bovine serum albumin (66
kDa), carbonic anhydrase (29 kDa), and cytochrome C (12.4 kDa). Five hundred
microliters of purified SbnG, at a concentration of approximately 1 mg/mL, was applied
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onto the gel filtration column coupled to a ÀKTA FPLC. The protein was monitored by
continuous absorption measurements at 280 nm and elution was controlled with a flow
rate of 0.2 mL/min.

3.2.5. Analytical Ultracentrifugation (Sedimentation Equilibrium)
Prior to the start of sedimentation analysis, purified SbnG was exhaustively buffer
exchanged into 50 mM HEPES pH 7.4, 150 mM NaCl through a combination of
centrifugation using an Amicon® Ultra-0.5 10K filter column (Millipore Corp.) and
dialysis. The dialysis buffer was retained for use as the reference blank for all analyses.
Sedimentation equilibrium analyses were performed on a Beckman XL-A centrifuge with
a four-hole An-60Ti rotor. Each cell contained a 6-sector Epon charcoal centerpiece. The
initial absorbance of the SbnG sample loaded into the instrument was approximately 0.3,
yielding a protein concentration of approximately 10 pM. Sedimentation analysis was
carried out at 25 °C with a rotor speed of 10 000 rpm. Absorbance of the protein was
measured at 280 nm and readings in the absorbance range of 0.1 to 1.0 were obtained
from the centrifuge. Absorbance measurements were recorded in 0.002-cm radial steps
and averaged over 10 observations. Equilibrium of SbnG was achieved when absorbance
scans obtained at least 5 hours apart were identical. The partial specific volume of SbnG
was calculated to be 0.739 g/mL at 25°C. The solvent density was calculated to be 1.0083
g/mL at 25°C. By assuming a single ideal species (as suggested from prior gel filtration
analysis), the molar mass (M) was determined from a nonlinear least-squares best fit of
the absorbance data at a single speed (at equilibrium) to the equation:
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where C is the concentration at radius r, C is the solute concentration at reference
distance F, co is the angular velocity of the rotor, v is the partial specific volume of the
solute, p is the solvent density, R is the gas constant, and T is the temperature in kelvin.
All data analysis was performed using the GraphPad Prism 5 software package.

3.2.6. Staphyloferrin B synthesis and degradation assays
Staphyloferrin B was prepared as previously described (2,3). Enzymes were removed
from the staphyloferrin B (SB) reaction mixture by centrifugation through an Amicon®
Ultra-0.5 10k filter column (Millipore). For assays to assay the ability of SbnG to degrade
Fe-SB, the filtrate was supplemented with 3 mM FeCfi and centrifuged at 18,000 x g to
remove insoluble material. Twenty-five pL of this filtrate was incubated with 10 pM
purified SbnG in buffer consisting of 20 mM sodium phosphate, pH 7.4, with, or without,
1 mM MgCb or with, or without, 1 mM MnCfe. Reactions were incubated overnight in
the dark at room temperature and then analyzed by LC-ESI-MS using methods as
previously described (2,3).

3.2.7. Citrate synthase assays
Routine assays for citrate synthase activity used the 5,5'-dithiobis-(2-nitrobenzoic
acid) (DTNB) method as originally described (18). In principal, any liberated coenzyme
A which would contain a free thiol group would react with a DTNB molecule. This
reaction causes splitting of the DTNB molecule to TNB' anions and one of these anions
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would be covalently attached to coenzyme A while the remaining TNB' anion possesses
an assayable absorption maximum at 412 nm. The optimization of reaction conditions
were performed with temperatures ranging from 4°C to 55°C, NaCl concentrations
ranging from 0 M to 1.2 M, and pH values of 4 to 10 (50 mM succinate buffer pH 4-6, 50
mM HEPES pH 7-8, and 50 mM CHES pH 9-10). Subsequent to optimization, and
unless otherwise stated, all further enzyme reactions performed throughout the study
contained 50 mM HEPES, pH 8.0, 300 mM NaCl, 0.1 mM acetyl-coenzyme A (Sigma),
0.2 mM oxaloacetate (Sigma), and 10 pM SbnG, and the reaction was carried out at 37°C
for 16 hours. A working concentration of 0.1 mM DTNB was added to each reaction to
detect activity and absorbance was measured at 412 nm using a Varian Cary 50 UV-vis
spectrophotometer. The extinction coefficient 14150 M '1 cm'1 was used for the TNB
dianion.
To test the effect of potential inhibitors on SbnG activity, the optimized enzyme
assay (see above) was performed in the presence of various concentrations of sodium
citrate (Sigma), ATP (Roche), NADH (Sigma), a-ketoglutarate (Sigma), L-2,3diaminopropionic acid (Iris Biotech GmBH), MgCf, or CaCl2 . Each assay included an
enzyme-free reaction in identical reaction conditions to serve as a blank. Note that
enzyme activity increased in a linear manner with respect to increasing enzyme
concentration and the presence of 20% (w/v) polyethylene glycol (PEG-8000) only
increased the activity by two-fold.
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3.2.8. SbnG Enzyme Kinetics
SbnG (citrate synthase) enzyme reactions were performed under optimal
conditions (see above) with various concentrations of oxaloacetate (0.012 mM to 3.2
mM) or acetyl-CoA (0.025 mM to 1.6 mM). Reactions were allowed to incubate for 10
minutes (for which the activity of the enzyme was still linear over time) and the
absorbance at 412 nm was measured. Data were fitted to nonlinear regression analysis
with a least-squares best fit to the Michaelis-Menten enzyme kinetic model. Kinetic
parameters and analysis were solved using the GraphPad Prism 5 software package.

3.2.9. Staphyloferrin B synthesis using SbnCEFGH enzymes
Enzyme reactions for the synthesis of staphyloferrin B that incorporated SbnG,
oxaloacetate and acetyl-CoA, in place of citrate, were performed using a two-step, twopot reaction so as to avoid the inhibitory effects on SbnG activity by staphyloferrin B
precursors and reaction components. Briefly, SbnG was incubated with oxaloacetate and
acetyl-CoA under optimal conditions, described above, for 16 hours. SbnG was then
removed from this reaction mixture by centrifugation through an Amicon® Ultra-0.5 10K
filter column (Millipore) at 14,000 x g for 15 min. The resulting filtrate was then
incubated with 1 mM a-ketoglutarate, 2 mM L-2,3-diaminopropionic acid, 0.5 mM
MgCl2 , 5 mM ATP, 0.5 mM pyridoxal-5’-phosphate (PLP), and SbnC, SbnE, SbnF, and
SbnEI (each at 10 pM). This reaction mixture was allowed to incubate for 16 hours at
room temperature in the dark.
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3.2.10. Mass Spectrometry Analysis
Enzyme reaction mixtures were subjected to centrifugation in an Amicon® Ultra0.5 10K filter column (Millipore) at 14,000 x g for 15 min remove all proteins prior to
LC-MS/MS analysis. The resulting filtrate was injected directly into an LC-MS/MS
system consisting of an Agilent HPLC 1100 with a Phenomenex Synergi Hydro-RP
column (250 x 1.0 mm, 4 pm, 80 A) coupled to a Q-TOF (micro, Waters) mass
spectrometer. Chromatography separation was carried out at a flow rate of 50 pL/min
with a gradient which started and held at 0% B for 10 minutes, then increased to 95% B
over 10 minutes, held at 95% B for 2 minutes, then returned to 0% B over 2 minutes. A
30-minute equilibration time was permitted before each sample injection. Solvent A was
water and solvent B was acetonitrile and both solvents contained 0.3% formic acid. LCMS analysis was performed with electrospray ionization in negative ion mode with a scan
range 100 to 700 m/z. Collision induced dissociation (CID) was performed with a mass
range 60 to 500 m/z using argon as collision gas. Variable collision energy of 15 to 30
volts was applied to obtain an informative fragmentation spectrum.

3.2.11. Disk diffusion bioassays
Disk diffusion bioassays were performed as described (11). Five pL aliquots of in
vitro enzyme reactions (reactions are described above) were mixed with 5 pL of 50 pM
FeCb prior to spotting onto sterile paper disks that were subsequently placed onto Trisminimal-succinate agar seeded with 1 x 104 bacteria per mL; bacteria used were S.
aureus RN6390 and its isogenic sirA mutant. Growth promotion, as measured by the
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diameter of the growth halo around each disk, was determined after 36 h incubation at
37°C.

3.2.12. Chemical detection of siderophore activity
To measure levels of siderophore activity, chrome azurol S (CAS) shuttle solution
(19) was prepared. In the case of in v/Yro-synthesized SB, 50 pL of the enzyme reaction
mixture (reactions are described above) were removed and diluted in 450 pL of deionized
water followed by 500 pL of CAS shuttle solution in a 1-mL spectrophotometer cuvette.
The mixture was then incubated in the dark for 45 min before absorbance readings (at
630 nm) were performed as described (11).

3.3. Results
3.3.1. Homologues of sbnG are found in siderophore biosynthetic gene clusters
In previous work, it was demonstrated that synthesis of the S. aureus siderophore
staphyloferrin B could be carried out in vitro using only the three synthetase enzymes,
SbnC, SbnE, and SbnF, and a decarboxylase SbnH, along with the substrates citrate, aketoglutarate, and L-2,3-diaminopropionic acid (Dap) (Chapter 2). Although encoded
from within the iron-regulated sbn operon, SbnG was clearly not required for
staphyloferrin B synthesis and its function remained elusive. Searches of the databases
revealed that an sbnG homologue, acsB, was present in the gene cluster for
achromobactin biosynthesis in Pseudomonas syringae B728a (46% identity to SbnG) and
Dickeya dadantii 3937 (48% identity to SbnG) (see Figure 3.1).

Moreover, the

vibrioferrin biosynthetic gene clusters from Pseudomonas aeruginosa PA7 and
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Xanthomonas oryzae KACC10331 also contain sbnG homologues annotated as
PSPA73088 (37% identity to SbnG) and mhpE (36% identity to SbnG) (Figure 3.1).
Interestingly, an sbnG homologue is absent from the vibrioferrin biosynthetic operon in
Vibrio parahaemolyticus RIMD2210633. Of note, staphyloferrin B, achromobactin, and
vibrioferrin (Figure 3.1) are each citrate-based siderophores.
SbnG has been annotated as a 2-dehydro-3-deoxyglucarate aldolase and
bioinformatic analyses reveal that the closest homologues are the characterized metaldependent class II aldolases HpcH, YfaU, and DDGA (20, 21, 22) (Table 3.1-3.3), These
bioinformatic predictions reveal potential functions of SbnG and this information will be
put to use in a later section. The protein is 259 amino acid protein with a theoretical
molecular mass of 28718.8 Da and a pi of 5.46. In order to study the function of this
protein, SbnG was overexpressed and purified to greater than 99% homogeneity as
estimated by SDS-PAGE (Figure 3.2) and the purity of the protein was further confirmed
by mass spectrometry.
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Figure 3.1. Structures and biosynthetic gene clusters for 3 representative NRPSindependent, a-hydroxycarboxylate-containing siderophores. Chemical structures for
citric acid-containing staphyloferrin B, achromobactin and vibrioferrin (A). Gene clusters
for staphyloferrin B, achromobactin and vibrioferrin (B). The name of the siderophore
whose production is directed by each cluster is listed on the left along with the bacterial
genome from which the information is taken. Where present, transporter-encoding loci
are also indicated. The sbnG homologs in each cluster (absent in the V. parahaemolyticus
cluster) are highlighted with an asterisk.
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Table 3.1. NCBI BLAST search results for SbnG from S. aureus strain Newman.
Asterisks denote SbnG homologues that are also found in siderophore biosynthetic gene
clusters illustrated in Figure 3.1.
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Table 3.2. Phyre (Protein Fold Recognition Server) search results for SbnG from S.
aureus strain Newman.
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Table 3.3. HHpred (homology detection and structure prediction server) search
results for SbnG from S. aureus strain Newman.
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Figure 3.2. Purification of SbnG. 15 micrograms of protein are loaded in each well and
the SDS-PAGE gel was stained with coomassie blue. Protein is loaded from different
stages of SbnG purification, as follows: elution after nickel-affinity (lane 1), flow-through
from nickel-affinity column after His-tag removal from SbnG (lane 2), and mono-Q ion
exchange chromatography (lane 3). Lane containing protein molecular weight standards
is labeled (M). Mass spectrometry confirmed that the purified protein shown in lane 3
has a mass of 29 293 Da, closely matching the expected theoretical mass of 29 289 Da for
the His6-tag-cleaved SbnG protein.
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3.3.2. SbnG does not degrade ferric-staphyloferrin B
As stated above, SbnG was not required for staphyloferrin B synthesis (Chapter 2). SbnG
shares similarity with carbon-carbon bond-cleaving aldolases (Table 3.1-3.3) and citrate
lyases (specifically the P-subunit), the latter of which perform a retro-aldol condensation
reaction on citrate to form oxaloacetate and acetate (20).

Therefore, we initially

speculated that SbnG might play a role in iron release from staphyloferrin B, once
internalized, by cleaving the siderophore. We tested for this activity by incubating SbnG
with ferric-staphyloferrin B and, using LC-MS, monitoring for the breakdown of
staphyloferrin B and the generation of new ion species. As demonstrated in Figure 3.3,
we were not able to detect SbnG-dependent breakdown of ferric-staphyloferrin B.
Common divalent metals used by aldolases are magnesium and manganese (21-24).
Therefore, reactions were performed in the presence of either magnesium or manganese
but again, we were unable to detect decreases in staphyloferrin B levels or any new mass
ions that corresponded to potential degradation products of the siderophore (data not
shown).

3.3.3. SbnG is a citrate synthase
Since we were unable to demonstrate staphyloferrin B-degrading activity for SbnG, we
investigated whether it was involved in the formation of precursors that would feed into
staphyloferrin B biosynthesis, rather than possessing a function similar to its homologues
such as degrading carbohydrates (e.g. function of DDGA or YfaU) or aromatic
compounds (e.g. function of HpcH). As illustrated in Figure 1, the genomic context for
sbnG and homologs is the biosynthetic gene cluster for carboxylate-type siderophores,
specifically those containing citrate and a-ketoglutarate. Initial clues to the functional
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Figure 3.3. SbnG does not break down staphyloferrin B. LC-MS of the 447.2 Da ion
from samples of staphyloferrin B (retention time 3.91 min) incubated with (top) or
without (bottom) SbnG.
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assignment of SbnG stemmed from the observation that SbnG shares modest homology
with malate synthase (Table 3.1-3.3) which condenses glyoxylic acid and acetyl-CoA to
yield malic acid (25-27). Our next clue arose from the significant similarity of SbnG with
macrophomate synthase (Table 3.1-3.3), which catalyzes a series of decarboxylation,
carbon-carbon bond formation, and dehydration reactions to convert oxaloacetate and 2pyrone into benzoate (macrophomic acid) (28,29). However, rather than generating malic
acid or macrophomic acid, which are not relevant precursors to staphyloferrin B, we
hypothesized that SbnG may at least share partial substrate specificity with malate and
macrophomate synthases for acetyl-CoA and oxaloacetate, respectively. The result would
be generation of citric acid by SbnG through an aldol condensation (carbon-carbon bond
formation) between acetyl-CoA and oxaloacetate, despite the similarity of this enzyme to
functionally characterized class II aldolases, which catalyze retro-aldol reactions (carbon
carbon bond cleavage).
Purified SbnG was incubated with proposed substrates oxaloacetate and acetylCoA and the DTNB assay originally described by Srere was employed to monitor for
enzyme-dependent release of coenzyme A (18). An increase in TNB ' anions over time
was observed when SbnG was incubated with acetyl-CoA in the presence of oxaloacetate
but not glyoxylate (Figure 3.4). Moreover, there was no increase in coenzyme A
formation observed over time, in the absence of oxaloacetate or acetyl-CoA (Figure
3.4B). A consistent basal level of coenzyme A formation was observed most likely to due
instability of acetyl-CoA in the incubating conditions, or that SbnG may exhibit minor
deacetylase activity. SbnG-dependent malate synthase activity (i.e. reactions containing
glyoxylate and acetyl-CoA) was not detectable even when reactions contained MgCb,
which is normally required for malate synthase activity (25-27) (data not shown).
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Figure 3.4. SbnG hydrolyzes acetyl-CoA in the presence of oxaloacetate but not
glyoxylate. In panel A, SbnG was incubated with glyoxylate and acetyl-CoA and the
amount of HS-CoA generated was determined using the DTNB assay (see Methods). In
panel B, the reactions were the same as those in panel A, except that glyoxylate was
substituted for oxaloacetate.
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Employing the same assay, we characterized optimal enzyme conditions for temperature
(37°C), salt (0.3-1 M) and pH (8.0) (Figure 3.5). Of particular note, results indicated that
enzyme activity was poor in buffer containing less than 0.3 M NaCl.
We next confirmed the observed activity from the DTNB assays by subjecting the
SbnG reaction mixtures to LC-ESI-MS/MS analysis to examine for the [M-H]' ion of
citric acid at 191.1 Da. Selected-ion chromatograms for the 191.1 mass ion species of
four different reactions showed that only the full SbnG reaction (Figure 3.6A, top panel)
yields a prominent chromatographic peak with retention time at 7.75 minutes which
contain the predicted mass ion for citric acid. When enzyme or substrates were omitted
from the reaction, the peak was not detected. Collision-induced dissociation (MS/MS)
was used to fragment the 191.1 Da mass ion into daughter ions, yielding the identical ion
profile to that of a citric acid standard (Figure 3.6B). These data confirm that SbnG
condenses oxaloacetate and acetyl-CoA to form citric acid. Importantly, mass
spectrometry analyses of the pure SbnG preparation used for the assays did not reveal any
contaminating mass ions that corresponded to the theoretical masses of E. coli citrate
synthase (48014.85 Da) or methylcitrate synthase (43102.99 Da) (data not shown).

3.3.4. SbnG obeys Michaelis-Menten kinetics
Steady-state kinetic parameters were determined for SbnG with respect to substrates
oxaloacetate and acetyl-CoA. For oxaloacetate, the values were Km= 0.16 ± 0.05 mM,
and &cat= 27.92 ± 2.14 min'1(Figure 3.7A). For acetyl-CoA, the kinetic parameters were
Km= 0.43 ± 0.07 mM, and kcat= 87.79 ± 5.33 min'1(Figure 3.7B).
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Figure 3.5. Optimization of SbnG enzymatic activity. SbnG was incubated overnight
in the presence of oxaloacetate and acetyl-CoA, and the amount of HS-CoA generated
was determined using the DTNB assay (see Methods). For each parameter tested, the
calibrator used (arbitrarily set to 100% activity) was the condition giving the highest
activity recorded.
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Figure 3.6.

SbnG is a citrate synthase. A) LC-ESI-MS analysis of reactions for

formation of mass ion species 191.1, corresponding to that of citric acid. Full reaction
contained SbnG, oxaloacetate, and acetyl-CoA and other reactions shown are those where
one component, as indicated, was omitted. B) MS/MS of 191.1 ion from either a citric
acid standard or the full SbnG reaction.
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Figure 3.7. SbnG follows Michaelis-Menten kinetics. The DTNB assay was employed
to measure SbnG steady-state kinetics with respect to both oxaloacetate and acetyl-CoA.
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3.3.5. Identification of SbnG inhibitors
Previously, we have demonstrated that staphyloferrin B synthetases SbnC, SbnE and
SbnF, along with a decarboxylase, SbnH, and substrates citrate, a-ketoglutarate and L2,3-diaminopropionic acid (Dap) would efficiently synthesize staphyloferrin B. Given
that SbnG could generate citrate, we attempted to generate staphyloferrin B by adding
SbnG, oxaloacetate and acetyl-CoA to the biosynthetic assay in place of citrate. These
reactions failed to yield any significant amount of staphyloferrin B. Thus, we investigated
whether any of the reaction components were acting as inhibitors towards the citrate
synthase activity of SbnG. Known inhibitors of the TCA-cycle citrate synthase are citric
acid, NADH, and ATP (30-34), and ATP is present in the staphyloferrin B biosynthesis
reaction because it is required for NIS synthetase function. In contrast to the TCA-cycle
citrate synthase, SbnG activity was not significantly inhibited by citric acid at
concentrations up to 10 mM (Figure 3.8). ATP inhibited SbnG activity up to 40% at 10
mM ATP, while NADH inhibited SbnG activity approximately 75% at the 10 mM
concentration. We also examined possible effects of staphyloferrin B biosynthetic
precursors on SbnG activity, which may highlight important regulatory features of the
enzyme in the context of staphyloferrin B synthesis in the cell. Inhibition by aketoglutarate was similar to that of NADH, with approximately 50% inhibition at 5 mM
a-ketoglutarate and 70% inhibition at 10 mM. However, the most notable inhibitor tested
was L-2,3-diaminopropionic acid, with 50% inhibition of activity at 0.5 mM and up to
90% inhibition at a 10 mM concentration of this siderophore precursor (Figure 3.8).
Interestingly, SbnG does not demonstrate a metal requirement for activity (Figures 3.4
and 3.6), despite the fact that many of its homologues are known to bind metal as a
requirement for catalysis (21-23,27,35). While the enzyme is relatively unaffected by
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calcium to at least a concentration of 10 mM, magnesium proved to be a strong inhibitor
with greater than 50% and 75% inhibition at 5 mM and 10 mM MgCb, respectively
(Figure 3.8). In agreement, mass spectrometry analyses of SbnG reactions incubated in
the presence of 10 mM MgCh confirmed a substantial decrease in the amount of the citric
acid ion species.

I

160

Figure 3.8. Identification of SbnG inhibitors. Enzyme assays were carried out as
described in the methods section. Percent activity is reported as a percentage of the
activity relative to an assay lacking the indicated components.

Concentration (mM)
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3.3.6. SbnG does not require divalent metals for activity
As already mentioned, many of SbnG’s homologues are metal-dependent enzymes
and the presence of a divalent metal is required for activity. However, consistently in this
study and in contrast to its homologues, SbnG does not require a divalent metal for
activity. In fact, the presence of increasing concentrations of metal appears to inhibit the
activity of SbnG instead. To rule out the possibility that the observed activity thus far is
due to a small percentage of the purified protein containing bound metal, purified SbnG
was treated with greater than 50-fold excess of EDTA (metal chelator) prior to incubation
with oxaloacetate and acetyl-CoA. This EDTA treatment would ensure minimum
contamination of metals with the enzyme. Figure 3.9 illustrates that even after treatment
of SbnG with greater than 50-fold molar excess of EDTA, SbnG activity remains at
greater than 90% of the non-EDTA treated enzyme. Furthermore, inductively-coupledplasma mass spectrometry (ICP-MS) of the EDTA-treated enzyme showed only trace
amounts of contaminating metals that were not at equimolar with enzyme concentration
(data not shown). Also, ICP-MS of excess metal-treated SbnG showed very low retention
of metal by the protein after washing (data not shown), which indicates that metal binding
by SbnG is likely to be very weak and thus only high concentrations would be sufficient
to force the protein to bind the metal leading to activity inhibition. This demonstrates that
SbnG indeed does not require a divalent metal for activity and in fact, addition of
inhibitory concentrations of magnesium or calcium (as in Figure 3.8) once again
inhibited

the

activity

of

EDTA-treated

SbnG

(Figure

3.9).
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3.3.7. SbnG-generated citric acid can be used as a substrate for downstream
staphyloferrin B biosynthesis
Due to the inhibitory effects of certain staphyloferrin B precursors on SbnG
activity (Figure 3.8), it is not feasible to set up a one-pot reaction mixture that contained
five Sbn enzymes (SbnCEFGH) with all precursors and cofactors what would be required
to make staphyloferrin B in vitro. Therefore, a two-pot reaction strategy was established
in which SbnG was incubated separately with oxaloacetate and acetyl-CoA to allow for
production of citric acid. The resulting reaction mixture was added along with a-KG,
Dap, MgCl2 , ATP, the three siderophore synthetases (SbnCEF) and decarboxylase
(SbnH). After overnight incubation at room temperature, the reaction mixture was CAS
positive (i.e. had siderophore activity) and promoted the iron-restriced growth of S.
aureus in a SirA-dependent manner (data not shown and see Chapter 2). These
observations are in agreement with previous reports of successful synthesis of
staphyloferrin B in vitro (Chapter 2). Indeed, LC-ESI-MS analysis of the reaction mixture
confirmed the presence of the characteristic mass ion of staphyloferrin B at [M-H]"=447.1
Da, which is a spectra identical to those already presented in Chapter 2.
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Figure 3.9. SbnG does not require divalent metals for activity. Purified SbnG was
treated with and without >50-fold molar excess of EDTA prior to incubation with
oxalacetate and acetyl-CoA. Activity was measured using the DTNB assay. Additional
magnesium or calcium was added to reactions at the concentrations indicated. All
activities reported are relative to the reaction containing non-EDTA treated SbnG that is
arbitrarily set at 100% activity.
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3.3.8. SbnG forms a multimeric complex in solution
It has been established that class II metal-dependent aldolases (Table 3.1-3.3) can form
physiologically relevant homohexamers (21-23,27,28,35). Similarly, it is known that type
I citrate synthase from Gram-positive bacteria and eukaryotes form homodimers (36-38)
and, interestingly, type II citrate synthases from Gram-negative bacteria form
homohexamers (39-42). Therefore, we investigated possible oligomerization of SbnG in
solution. Analysis of purified SbnG by analytical size exclusion chromatography revealed
a single eluting species with Ve = 12.2 mL (Figure 3.10). After factoring in the void
volume (V0) and matching the Ve/V0 to internal calibration standards (Figure 3.10, inset),
the calculated molecular weight of the eluting species was approximately 188 kDa, a
value that corresponds to roughly 6.4 monomer units of SbnG. For a more precise
investigation into the oligomeric state of SbnG in solution, we performed sedimentation
equilibrium analysis on the purified protein. Analysis of the enzyme at rotor speed 10 000
rpm at equilibrium yielded data which agreed well with a hexamer model of fitting
(Figure 3.11). Based on the fitted data, the calculated molecular weight of the species at
equilibrium was 170 kDa, which is within 3% error of the theoretical hexameric
molecular mass of purified SbnG (175.2 kDa).
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Figure 3.10. Size-exclusion chromatography of SbnG. The chromatogram was
obtained from size-exclusion analysis of purified SbnG using a Superdex 200 column at a
flow rate of 0.2 mL/min. The running buffer consisted of 50 mM HEPES, pH 7.4, and
150 mM NaCl. The absorbance was recorded at 280 nm. The elution volumes of
molecular mass standards are shown at the top of the chromatogram. The inset is a
calibration curve for the Superdex 200 column. The elution volume of the standards is
represented as a ratio of the elution volume of the protein standard to the void volume of
the column. The ratio of the elution volume of SbnG is shown, and corresponds to a
molecular mass of 188 kDa.
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3.4. Discussion
The work reported here represents the first attempt to probe the biochemical
function of a putative aldolase, SbnG, encoded from within the staphyloferrin B
biosynthetic operon in S. aureus. Homologs of SbnG are also encoded from within the
biosynthetic loci for other citrate-based siderophores. In this study, we have demonstrated
that SbnG catalyzed an aldol condensation reaction involving acetyl-CoA and
oxaloacetate to yield citric acid. In the context of the biosynthesis of citrate-containing
siderophores, a specialized route to citric acid production would be advantageous to
bacteria that are undergoing an 'iron-sparing response' (15) which is characterized by
down-regulation of the TCA cycle which would lead to decreasing synthesis of key
metabolic acids that may serve as siderophore precursors. Here, we have demonstrated
the ability to couple the SbnG-generated citric acid with other staphyloferrin B
synthetases and precursors to form biologically active staphyloferrin B. In light of the
central metabolic changes that occur during growth under iron-limitation, thus limiting
availability of citrate and a-KG through the TCA cycle, S. aureus must have other routes
to provide these key intermediates to generate staphyloferrin B (Figure 3.1).
Interestingly, the S. aureus genome is predicted to encode enzymes pyruvate carboxylase
(PycA), aspartate transaminase, and glutamate dehydrogenase (GudB) that are known to
be involved in the replenishment of TCA cycle intermediates when levels decrease in the
cell due to consumption in biosynthetic pathways (a phenomenon known as anaplerotic
reactions). Specifically, oxaloacetate levels can be restored by enzymes pyruvate
carboxylase and aspartate transaminase. Furthermore, the 'iron-sparing response' is also
predicted to upregulate levels of acetyl-CoA (15) which is catalyzed by the pyruvate
dehydrogenase (PhdA-PhdB) complex. Therefore, the availability of both oxaloacetate
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and acetyl-CoA through these routes would ensure precursors are available for SbnG to
generate citric acid. For a-ketoglutarate, this staphyloferrin B precursor could be formed
through the anaplerotic route as well, via deamination of glutamate by glutamate
dehydrogenase (GudB).
It is interesting to note that the staphyloferrin A biosynthetic locus does not
include an sbnG homologue especially since staphyloferrin A requires two molecules of
citrate per siderophore molecule. It is possible that in S. aureus, SbnG activity would
provide sufficient citrate levels for both staphyloferrin A and staphyloferrin B
biosynthesis. It is interesting to note that in S. aureus, a mutant deleted for the entire
staphyloferrin B locus (i.e. including sbnG) still synthesizes staphyloferrin A, indicating
that the cell has enough citric acid to supply staphyloferrin A synthesis during iron
limitation. However, it is also interesting to note that this mutant has a longer lag period
during iron limited growth than the mutant containing a staphyloferrin A locus deletion.
The reasons for this phenomenon are not understood, and there are several possible
explanations, but one factor might be that in the sbn deletion mutant, the absence of sbnG
delays, or initially limits, the synthesis of staphyloferrin A. Other examples of citratebased siderophore systems that lack an sbnG homologue include aerobactin, rhizoferrin,
and petrobactin. Interestingly, these citrate-based siderophores, like staphyloferrin A,
possess a near-symmetrical molecular structure whereas the other citrate-based
siderophores staphyloferrin B, achromobactin, and vibrioferrin do not possess symmetry
in their structures. Thus, there is an intriguing correlation between the presence of this
gene in the biosynthetic gene clusters of asymmetrical siderophores and its absence from
biosynthetic systems of near-symmetrical siderophores. The implications of this
observation are unclear at this point.
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SbnG formed stable hexamers in solution. The hexameric arrangement of SbnG
protomers is in agreement with that of aldolases that share similarity with SbnG (21
23,27,28,35). However, the lack of metal-dependence for SbnG activity is one striking
difference between SbnG and the metal-dependent class II aldolases. Indeed, our results
demonstrated that divalent metals such as calcium and magnesium actually had inhibitory
effects on SbnG activity. This observation leads us to hypothesize that SbnG is subject to
regulation by divalent metals in which the metallic species may be acting as a competitive
inhibitor towards one of the substrates for SbnG. This is plausible since the location of the
divalent metal is coordinated at the active site for enzymes with the same overall fold as
SbnG. The staphyloferrin B precursors a-ketoglutarate and L-2,3-diaminopropionic acid
also appear to inhibit the activity of SbnG, and thus it is tempting to speculate on the
existence of an intricate post-translational regulatory system within the staphyloferrin B
biosynthetic pathway. Perhaps upon quick return to an iron-replete cellular status,
accumulated levels of unconsumed staphyloferrin B precursors would serve as rapid
inhibitory signals to halt further siderophore production as the demand for siderophore
declines. Indeed excess culture feeding of L-2,3-diaminopropionic acid has been shown
to inhibit staphyloferrin B production (7). Although the concentration of inhibitors used
in this study appear high and may not be physiologically relevant, these concentrations
may be approached in the vicinity of the enzyme complex. Investigating potential
regulatory mechanisms of staphyloferrin biosynthesis remains an ongoing effort of our
laboratory.
Similar to what we observed for SbnG, E. coli citrate synthase is sensitive to
inhibition by divalent metals such as Mg2+ and Ca2+ (43). Furthermore, Faloona and Srere
noted enhanced activity in the presence of potassium, ammonium and sodium ions (43).
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We report a similar phenomenon of increased enzyme activity with increasing NaCl
concentrations with SbnG. It has been shown that a-ketoglutarate and NADH exhibit
allosteric inhibition on the hexameric Gram-negative citrate synthase (30,41,42,44,45).
Interestingly, Weitzman and Dunmore demonstrated that citrate synthase from Gram
negative facultative anaerobic bacteria (such as E. coli) show sensitivity to aketoglutarate inhibition, whereas those from strict aerobic Gram-negative bacteria are not
affected by a-ketoglutarate (41). Moreover, a-ketoglutarate and NADH do not appear to
largely affect the activity of the dimeric enzyme from Gram-positive bacteria or
eukaryotes (37,38,41,42,46,47). However, Robinson et al. (1983) still observed slight
inhibition of the activity of dimeric citrate synthase by NADH at concentrations similar to
the ones used in this study (while only 0.1 mM NADH is required for significant
inhibition of the hexameric citrate synthase) and noted that these effects may be due to
isosteric inhibition because of the similar structure of acetyl-CoA with nucleotidecontaining molecules; thus NADH likely binds into the acetyl-CoA binding site of the
enzyme. It should be noted that presence of 0.1-0.2 M KC1 was sufficient to relieve the
inhibitory effects by NADH or a-ketoglutarate on E.coli citrate synthase (43-45). In
contrast, our SbnG assays contained a similar concentration of salt (NaCl; 0.3 M),
required for enzyme activity, but did not render the enzyme immune to the inhibitory
effects of the molecules tested. Although Gram-positive or eukaryotic citrate synthase is
unaffected by NADH or a-ketoglutarate, it remains sensitive to potent inhibition by ATP
(while ATP has a lesser effect on Gram-negative citrate synthase) (30,38,46). It has been
established that ATP inhibition of Gram-positive and eukaryotic citrate synthase occurs
through an isosteric rather than allosteric manner (30). Therefore, SbnG appears to share
a set of inhibitors that are common to both classes of citrate synthases.
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In terms of kinetic parameters for citrate synthase activity, the bacterial TCA cycle
citrate synthases generally have higher Km values than the eukaryotic enzymes. In
comparison, the values for SbnG are approximately 10-fold higher than the bacterial TCA
enzyme and approximately 100-fold higher than the eukaryotic versions (Table 3.4).
Surprisingly, very few steady-state kinetic parameters of the condensation reaction for
aldolases have been reported and thus comparisons with SbnG were difficult. For
instance, fructose-1,6-bisphosphate aldolase exhibits Km values of 95 pM and 1100 pM
for dihydroxyacetone phosphate and glyceraldehyde-3-phosphate, respectively (48).
These values are comparable to those obtained for SbnG with respect to acetyl-CoA and
oxaloacetate for a condensation reaction. In addition, we were interested in comparing
kinetic constants that are measured for the cleavage reaction catalyzed by class II
aldolases (such as YfaU, HcpH, DDGA, and Hpal) to the condensation reaction of SbnG
(Table 3.5). This will at least provide some perspective on the affinity of SbnG for its
substrates in comparison to the other aldolases. It appears that the kinetic constants of
several homologous aldolases in the aldol cleavage direction are comparable to the values
obtained for SbnG catalyzing a reaction in aldol condensation direction (Table 3.5).
Overall, the citrate synthase activity of SbnG is less efficient than both bacterial and
eukaryotic TCA cycle citrate synthases, but the reported activity is still relatively
comparable to its closest aldolase homologues.
Based on bioinformatics and SbnG sequence analysis alone, the initial prediction of
function for this enzyme would be an aldolase that catalyzes the retro-aldol reaction for a
certain sugar substrate. However, it is also well understood that proteins sharing a high
sequence similarity may actually perform different functions in vivo and in contrast,
proteins with low sequence similarity may actually perform similar functions. Although
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Table 3.4. Kinetic constants of various TCA cycle citrate synthases with respect to
oxaloacetate and acetyl-CoA. ND; Not determined from referenced study.
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Organism/
Source

Km
(Oxaloacetate),
HM

ACab
(Oxaloaceate),
s'1

Km
(AcetylCoA),
HM
430

ACati
(AcetylCoA),
s'1
1.46

Reference

This study

SbnG

160

0.47

Rat Heart

5.0

ND

4.6

ND

(36)

Rat Liver

3.6

ND

2.8

ND

(36)

Rat Kidney

4.8

ND

11.8

ND

(49)

Escherichia
coli

26

81

120

81

(50)

Bacillus
megaterium

12

ND

76

ND

(37)

7-15

ND

6.5-22

100

(51)

Bacillus
subtilis
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Table 3.5. Kinetic constants of various class II aldolases with respect to their
identified substrates. The enzymes DDGA HcpH (formerly Hpal), and YfaU will
catalyze the aldol cleavage of the listed substrates while SbnG and fructose-1,6biphosphate aldolase (FBP) will catalyze a condensation reaction between the two
corresponding substrates. All enzymes listed utilize magnesium as the catalytic divalent
metal (other than SbnG) unless otherwise stated. ND; Not determined from referenced
study.
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Enzyme
SbnG

Substrate
acetyl-coA
oxaloacetate

Km, [iM
430
160

*cat, (S'1)
1.46
0.47

Reference
This study
This study

FBP

dihydroxyacetone phosphate
glyceraldehyde-3 -phosphate

95
1100

2.00x10'3
1.80x10'3

(48)
(48)

DDGA

2-keto-3 -deoxy-D-glucarate

250

ND

(23)

HcpH

4-hydroxy-2-ketohexanoate
(with Co2+)

160

229.36

(52)

HcpH

4-hydroxy-2-ketopentanoate
(with Coi+)

380

353.46

(52)

HcpH

4-hydroxy-2-oxo-heptane-1,7-dioate

50

9.40

(21), (22)

YfaU

2-keto-3-deoxy-L-rhamnonate

78

0.40

(22)

YfaU

2-keto-3-deoxy-L-mannonate

140

0.30

(22)

YfaU

4-hydroxy-2-oxo-heptane-1,7-dioate

150

0.54

(22)
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class II aldolases such as YfaU and HcpH have been originally studied for catalyzing the
equilibrium-favoured retro-aldol reaction (carbon-carbon bond cleavage), other class II
aldolases such as DDGA, fructose-1,6-biphosphate aldolase, and fuculose-1 phosphate
aldolase are capable of performing a reaction in the condensation (carbon-carbon bond
formation) direction (23,35,53-56). In fact, Smirnov et al., 2007 studied a class II aldolase
from Achromobacter simplex that catalyzed the condensation between acetaldehyde and
a-ketobutyrate to form 4-hydroxy-3-methyl-2-keto-pentanoate. Furthermore, they even
demonstrated that the model aldolases YfaU and DDGA were capable of catalyzing the
identical condensation reaction involving the same substrates (57). Therefore, it is not
surprising that although SbnG exhibits similarity to class II aldolases, it has evolved into
a citrate synthase responsible for catalyzing a condensation reaction to form a central
precursor for staphyloferrin B biosynthesis.
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Chapter 4:
General discussion, conclusions, and future directions

184

4.1 Discussion and Conclusions
Staphylococcus aureus synthesizes two siderophores staphyloferrin A and
staphyloferrin B (1-4) that are subsequently transported through high-affinity (low
nanomolar K&) ABC transport systems HtsABC and SirABC, respectively (5-9). In
addition to utilization of its endogenously synthesized siderophores, S. aureus is also
capable of hijacking siderophores produced by other organisms (xenosiderophores) in the
environment by using the FhuBGC2-Dl/D2 transport system for hydroxamate-type
siderophores and the SstABCD transport system for catecholate-type siderophores (10
15). Biosynthesis of the two a-hydroxycarboxylate class siderophores staphyloferrin A
and staphyloferrin B is performed by NIS synthetases encoded within the sfa and sbn
gene clusters, respectively (16,17). The biosynthesis of staphyloferrin A utilizes a PLPdependent racemase (SfaC), two Type A’ NIS synthetases (SfaB and SfaD), and
substrates citrate and L-omithine (16). Meanwhile, the biosynthesis of staphyloferrin B is
much more complex and depends on the activities of a putative O-acetyl-L-serine
sulfhydrylase (SbnA), putative ornithine cyclodeaminase (SbnB), a PLP-dependent
decarboxylase (SbnH), a citrate synthase (SbnG), Type A synthetase (SbnE), Type B
synthetase (SbnC), and a Type C synthetase (SbnF). The substrates used in staphyloferrin
B biosynthesis are L-2,3-diaminopropionic acid (proposed product of SbnA and SbnB),
citrate (condensation product of oxaloacetate and acetyl-CoA via SbnG), and aketoglutarate (via citric acid cycle or anaplerotic pathways). Note that the Sbn auxiliary
enzymes provide a large fraction of substrates for the NIS synthetases. Furthermore, the
auxiliary enzyme SbnH is a critical enzyme midway in the biosynthesis of the
siderophore because it needs to decarboxylate the citryl-diaminopropionate intermediate
(product of SbnE) in order for the pathway to proceed onto SbnF. Characterization of

185

SbnG afforded knowledge on an upstream step in the staphyloferrin B biosynthetic
pathway originally proposed in Chapter 2. This step involved an SbnG-catalyzed aldol
condensation reaction between acetyl-CoA and oxaloacetate to form citrate which is the
carboxylate substrate for SbnE as well as being a hallmark component of staphyloferrin
B. Altogether, the work in this thesis represents the first biochemical investigation into
the functional roles of many enzymes encoded within the sbn operon. The result was the
unveiling of an intricate biochemical pathway leading to a rather simple yet superbly
useful molecule for S. aureus (Figure 4.1).
Iron is the fourth most abundant element on Earth and yet mammals and
microorganisms have been locked in an evolutionary arms race to acquire this metal.
From the secretion of iron-binding siderophores to the use of heme-scavenging proteins,
and the evolution of high-affinity transport systems, bacteria employ unparalleled
strategies in the quest for iron. Despite the efficiency of microbial iron uptake methods,
operating an iron acquisition system demands an enormous metabolic, biochemical, and
physiological commitment from the bacterium. Bacteria must possess the amino acids,
cofactors, and energy for synthesis of multiple large siderophore biosynthetic enzymes,
heme-scavenging proteins, and transport proteins. Furthermore, bacteria must spend more
energy for siderophore biosynthesis and active transport of siderophore-iron or heme-iron
complexes. Lastly, they must also prepare the enzymes necessary to degrade these ironchelate complexes in order to liberate the iron so that it may be used for cellular
processes. However, the role of iron in central physiology is so critical that the magnitude
of biochemical preparedness required is justified.
Although the focus of this thesis was on staphyloferrin B biosynthesis in S.
aureus, other structurally different siderophores are manufactured by different
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biosynthetic pathways and will employ NRPS, NIS, or NRPS-NIS synthetase strategies.
However, despite all this diversity in the design and evolution of siderophore structures
along with their respective biosynthetic and transport systems, they all share one purpose
- to acquire iron. One may ask why there is not a universal siderophore that is synthesized
and utilized by all bacteria such as an iron-chelate molecule like heme that is also used for
many central biochemical processes. Furthermore, why do different bacteria produce
different siderophores? Although some bacteria do synthesize the same siderophore such
as most enteric bacteria produce enterobactin (18) or that staphyloferrin B is produced by
both S. aureus and R. solancearum, the overall number of organisms known to produce
the same siderophore is relatively small. One advantage for the production of a unique
siderophore with regards to pathogens is to use them as stealth siderophores such as
petrobactin or salmochelin since the host innate immune protein siderocalin would not be
able to confiscate these siderophores (19-24). Furthermore, the ability to synthesize
multiple siderophores, as in the case of S. aureus with staphyloferrin A and staphyloferrin
B, might confer it with certain advantages depending on the growth conditions. Also note
that both staphyloferrins are non-catecholate siderophores, and thus they may be
considered as stealth siderophores that can dodge the scavenging properties of siderocalin
since this protein only recognizes catecholate siderophores. However, the advantage to
possessing two stealth siderophores remains unclear at this time.
Another intriguing aspect of siderophore biosynthesis is the efficiency of the
entire biosynthetic process. Thus far, there is no knowledge regarding how NIS
synthetases or the auxiliary enzymes are organized in vivo and how each enzyme is
localized relative to another. It is tempting to speculate that there must be some degree of
protein-protein interactions between the enzymes and that all associated biosynthetic
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enzymes are located within the same vicinity of the cell. This would ensure orderly and
efficient delivery of substrates and intermediates from one enzyme to the next rather than
requiring enzymes to wait for the random diffusion of a substrate across polar opposites
of the cytoplasm. Therefore, if an ordered complex of enzymes does exist, it is tempting
to further speculate that such a complex may localize near the effluxing protein so that
completion of siderophore synthesis is coupled to export of the molecule out of the cell.
Therefore, investigating potential protein-protein interactions in NIS synthetase systems
remain an unexplored avenue of research in this field.
The acquisition or evolution of a functional siderophore biosynthetic system must
have endured rigorous selection pressures to sample and incorporate the most appropriate
NIS or NRPS enzymes, the most efficient substrates to achieve the best iron-coordination,
and the correct auxiliary enzymes involved in tailoring and preparing the proper
siderophore precursors. Therefore, each organism with a different siderophore
biosynthetic system must have undergone this evolutionary process at some point in order
to develop the iron-scavenging tools they have today.
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Figure 4.1. Overall staphyloferrin B biosynthetic and transport pathway in S.
aureus. The complete proposed staphyloferrin B biosynthetic and transport pathway is
shown. The proteins involved are colour coded and can be matched back to the sir-sbn
operons at the bottom of the figure. The reactions catalyzed by SbnA and SbnB shown in
this figure are adapted from the proposed function of similar proteins involved in
viomycin biosynthesis (25). Although the exact enzymatic reactions of SbnA and SbnB
are currently still under investigation, they are likely to provide the L-2,3diaminopropionic acid utilized by the NIS synthetases to make staphyloferrin B. The
siderophore is synthesized by enzymes of the sbn operon and is then effluxed out into the
extracellular environment by a putative membrane efflux protein SbnD. Once
staphyloferrin B has captured an iron atom, the ferric-siderophore complex will return to
the cell via recognition by the high-affinity SirABC transport system.
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4.2. Future and ongoing directions
Aside from investigating potential protein-protein interactions between enzymes
of the sbn operon (as mentioned earlier), there are still several Sbn proteins that remain to
be biochemically characterized. The focus of this thesis was on functional
characterization of three NIS synthetases (SbnC, SbnE, and SbnF) and two auxiliary
enzymes (SbnG and SbnH), but two remaining biosynthetic (auxiliary) enzymes SbnA
and SbnB have not been functionally addressed. However, biological and preliminary
biochemical analysis of SbnA and SbnB activities in our laboratory have suggested that
they act together as a L-2,3-diaminopropionate synthase despite their predicted similarity
to putative serine sulfhydrylases or ornithine cyclodeaminases. The mechanism for the
synthesis of this staphyloferrin B precursor is still currently under investigation but we
hypothesize that SbnB catalyzes a deamination reaction of a specific amino acid and the
released ammonia molecule will be used as a nucleophilic substrate by SbnA to attack
(O-acetyl-) L-serine and generate L-2,3-diaminopropionic acid via a P-displacement
reaction. Since the functional characterization of SbnA and SbnB remain to be resolved,
in vitro preparations of staphyloferrin B in this thesis utilized commercially available L2,3-diaminopropionic acid to bypass the need for in vitro SbnA and SbnB activities.
In addition to the NIS siderophore synthetases and the auxiliary enzymes that are
directly involved in staphyloferrin B biosynthesis, the sbn operon also encodes two more
proteins named SbnD and Sbnl which have yet to receive much experimental
investigation. SbnD is predicted to be a membrane-bound exporter/effluxer protein that
transports staphyloferrin B from the cytoplasm to the extracellular environment after the
siderophore has been synthesized. Meanwhile, Sbnl may be involved in transcriptional
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proteins but does contain regions of the protein that are similar to DNA-binding proteins
or transcription factors. Thus plenty of uncharted territory still exists in the realm of
staphyloferrin B biosynthesis, metabolism, and transport in S. aureus.
Another intriguing aspect regarding staphyloferrin B precursors is the source of
citrate for S. aureus. Not only is citrate an important precursor for staphyloferrin B, but it
is also used twice per mole of staphyloferrin A. However, since an S. aureus sbn mutant
still can produce staphyloferrin A, this means that the source of citrate for this
siderophore must originate from the TCA cycle and perhaps SbnG would only contribute
very little to no citrate for staphyloferrin A biosynthesis. Certainly, in a wild-type strain
of S. aureus, the production of citrate from SbnG may be able to fuel staphyloferrin A
production to some degree, but the efficiency of crosstalking siderophore biosynthetic
pathways in S. aureus remains to be investigated. Furthermore, it almost seems that
SbnG’s citrate synthase activity was tailored specifically for staphyloferrin B
biosynthesis. Therefore, it would be interesting to observe how long the TCA cycle can
provide citrate to sustain staphyloferrin B biosynthesis (if any) under conditions of iron
starvation when sbnG is mutated. Perhaps, after extended periods of iron starvation, the
presence of an iron-regulated citrate synthase will serve to solve the citrate deficiency
issue that other bacteria may encounter. Conversely, studies involving the mutation of the
citZ gene (encoding the TCA cycle citrate synthase) in S. aureus will be able to
demonstrate whether SbnG alone is sufficient to provide all the citrate required for the
biosynthesis of both staphyloferrins. Lastly, we can also hypothesize that an S. aureus
sbnG citZ double mutant may no longer be capable of synthesizing any staphyloferrin due
to the complete inability to produce citrate. An S. aureus citZ mutant has been generously
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provided to our laboratory (courtesy of Dr. Greg Somerville, University of NebraskaLincoln) for these studies.
The work presented in this thesis will be an expansion to the rapidly advancing
knowledge regarding siderophore biosynthesis and this is especially true for NIS
siderophore systems. Elucidation of the biosynthetic pathway for staphyloferrin B
revealed the function of a type A, type B, and type C synthetase in the context of
staphyloferrin B biosynthesis. This work also involved functional characterization of two
novel siderophore biosynthetic auxiliary enzymes - a decarboxylase and a citrate
synthase. Uncovering an NIS siderophore biosynthetic pathway holds tremendous value
towards understanding the catalytic mechanisms and substrate specificities for
siderophore

synthetases.

For example, comparisons between enzymes of the

staphyloferrin B and achromobactin (26) biosynthetic pathways will allow for
identification of unique differences in similar siderophore synthetases that permit each
enzyme’s substrate specificity leading to the corresponding a-hydroxycarboxylate
siderophore. This would be possible through structural determination of each synthetase
along with site-directed mutagenesis studies of candidate catalytic residues. Therefore, it
may even be possible to engineer custom NIS synthetases that can recognize target
substrates in order to synthesize compounds of interest. Furthermore, NIS synthetases can
prove to be useful biocatalysts for the synthesis of pharmaceuticals similar to how NRPS
enzymes are used for this purpose (27). With more structural and mechanistic knowledge,
medicinal chemistry can be employed to design and synthesize novel inhibitors against
these enzymes. Since siderophores are virulence tools in diverse pathogens, inhibitors of
NIS synthetases would be effective antimicrobials that can lead a pathogen to iron
starvation.

193

S. aureus is a formidable pathogen with a wide range of strategies to ensure host
colonization and establishment of infection. However, despite its plethora of virulence
factors and cunningness, the survival of S. aureus, like any other organism in nature, is
still heavily weighted upon its ability to obtain nutrients from the environment and iron is
certainly no exception.

194

4.3. References

1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.

23.

Drechsel, H., Freund, S., Nicholson, G., Haag, H., Jung, O., Zahner, H., and Jung,
G. (1993) Biometals 6, 185-192
Haag, H., Fiedler, H. P., Meiwes, J., Drechsel, H., Jung, G., and Zahner, H. (1994)
FEMS Microbiol Lett 115, 125-130
Konetschny-Rapp, S., Jung, G., Meiwes, J., and Zahner, H. (1990) Eur J Biochem
191,65-74
Meiwes, J., Fiedler, H. P., Haag, H., Zahner, H., Konetschny-Rapp, S., and Jung,
G. (1990) FEMS Microbiol Lett 55, 201 -205
Beasley, F. C., Vines, E. D., Grigg, J. C., Zheng, Q., Liu, S., Lajoie, G. A.,
Murphy, M. E., and Heinrichs, D. E. (2009) Mol Microbiol 72, 947-963
Dale, S. E., Doherty-Kirby, A., Lajoie, G., and Heinrichs, D. E. (2004) Infect
Immun 72, 29-37
Dale, S. E., Sebulsky, M. T., and Heinrichs, D. E. (2004) J Bacteriol 186, 8356
8362
Grigg, J. C., Cheung, J., Heinrichs, D. E., and Murphy, M. E. J Biol Chem 285,
34579-34588
Grigg, J. C., Cooper, J. D., Cheung, J., Heinrichs, D. E., and Murphy, M. E. J Biol
Chem 285, 11162-11171
Courcol, R. J., Trivier, D., Bissinger, M. C., Martin, G. R., and Brown, M. R.
(1997) Infect Immun 65, 1944-1948
Beasley, F. C., Marolda, C. L., Cheung, J., Buac, S., and Heinrichs, D. E. (2011)
Infect Immun 79, 2345-2355
Sebulsky, M. T., and Heinrichs, D. E. (2001) J Bacteriol 183, 4994-5000
Sebulsky, M. T., Hohnstein, D., Hunter, M. D., and Heinrichs, D. E. (2000) J
Bacteriol 182, 4394-4400
Sebulsky, M. T., Shilton, B. H., Speziali, C. D., and Heinrichs, D. E. (2003) J Biol
Chem 278, 49890-49900
Sebulsky, M. T., Speziali, C. D., Shilton, B. H., Edgell, D. R., and Heinrichs, D.
E. (2004) J Biol Chem 279, 53152-53159
Cotton, J. L., Tao, J., and Balibar, C. J. (2009) Biochemistry 48, 1025-1035
Cheung, J., Beasley, F. C., Liu, S., Lajoie, G. A., and Heinrichs, D. E. (2009) Mol
Microbiol 74, 594-608
Miethke, M., and Marahiel, M. A. (2007) Microbiol Mol Biol Rev 71, 413-451
Hantke, K., Nicholson, G., Rabsch, W., and Winkelmann, G. (2003) Proc Natl
Acad Sci U SA 100, 3677-3682
Bister, B., Bischoff, D., Nicholson, G. J., Valdebenito, M., Schneider, K.,
Winkelmann, G., Hantke, K., and Sussmuth, R. D. (2004) Biometals 17, 471-481
Koppisch, A. T., Browder, C. C., Moe, A. L., Shelley, J. T., Kinkel, B. A.,
Hersman, L. E., Iyer, S., and Ruggiero, C. E. (2005) Biometals 18, 577-585
Fischbach, M. A., Lin, H., Zhou, L., Yu, Y., Abergel, R. J., Liu, D. R., Raymond,
K. N., Wanner, B. L., Strong, R. K., Walsh, C. T., Aderem, A., and Smith, K. D.
(2006) Proc Natl Acad Sci U S A 103, 16502-16507
Raffatellu, M., George, M. D., Akiyama, Y., Hornsby, M. J., Nuccio, S. P.,
Paixao, T. A., Butler, B. P., Chu, H., Santos, R. L., Berger, T., Mak, T. W., Tsolis,

195

24.
25.
26.
27.

R. M., Bevins, C. L., Solnick, J. V., Dandekar, S., and Baumler, A. J. (2009) Cell
Host Microbe 5, 476-486
Cendrowski, S., MacArthur, W., and Hanna, P. (2004) Mol Microbiol 51, 407-417
Thomas, M. G., Chan, Y. A., and Ozanick, S. G. (2003) Antimicrob Agents
Chemother 47, 2823-2830
Berti, A. D., and Thomas, M. G. (2009) J Bacteriol 191, 4594-4604
Felnagle, E. A., Jackson, E. E., Chan, Y. A., Podevels, A. M., Berti, A. D.,
McMahon, M. D., and Thomas, M. G. (2008) Mol Pharm 5, 191-211

Appendix

197

Figure SI. LC-ESI-MS data to identify mass ions consistent with proposed
staphyloferrin B biosynthetic intermediates. MS spectra focused on mass ranges for
identification of particular intermediates as discussed in the text (see Results in Chapter
2). Each data set resulted from reactions run in phosphate buffer (see Experimental
Procedures in Chapter 2) and was normalized to the intensity of a background mass ion
present in all samples.
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